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ABSTRACT OF DISSERTATION

ROLE OF PANCREATIC AMYLIN IN ALZHEIMER’S AND BRAIN
MICROVASCULAR PATHOLOGIES
Alzheimer disease (AD) and cerebral vascular disease (CVD) are common
causes of impaired cognition and behavior in humans. Epidemiological studies
have shown that AD and CVD development and progression associated with
metabolic risk factors including type 2 diabetes (T2D). However, the underlying
molecular mechanisms remain elusive, which hampers the development of
treatment and prevention strategies. Research results from our laboratory and
others have shown that amylin, a hormone secreted by the pancreas and involved
in glucose homeostasis, induces small-vessel-type pathologies and modulates
amyloid composition in both familial (genetically predisposed) and sporadic forms
of AD. The results indicate amylin as a potential molecular modifier of the course
of Alzheimer’s and brain microvascular pathologies.
The present work provides a basis for understanding the role of pancreatic
amylin in brain injury and neurologic deficits associated with aging and metabolic
dysfunction. First, we used brain tissues from humans with T2D and AD, and a rat
model expressing human amylin in the pancreas (the HIP rat), to test the impact
of amylin dysregulation on the brain. We found that high blood levels of amylin
promoted vascular accumulation of amylin leading to endothelial cell dysfunction
and microvascular injury. Amylin-mediated injury of the cerebrovasculature leads
to brain white matter disease and neurological dysfunction in HIP rats. Next, we
sought to understand the role of amylin in the development of AD pathology and
progression of the disease. Using brain tissues from humans with sporadic and
familial forms of AD, AD model rats expressing human amylin (ADHIP rats) and
AD model rats expressing non-amyloidogenic rat amylin, we found that high blood
levels of amylin modulates AD pathology via amylin-Aβ cross-seeding in the grey
matter and also contributes to non-AD molecular pathways such as injuries to
small blood vessels supplying the white matter. By staining and imaging of brain
amylin and Aβ, we showed that amylin accumulated in the brain parenchyma and
small blood vessels, and formed mixed plaques with Aβ. Elevated plasma amylin

with aging in ADHIP rats was associated with brain microvascular damage and
neurological dysfunction. Based on these studies, we inferred that amyloid-forming
amylin secreted by the pancreas modulates brain amyloid composition in both
sporadic and familial forms of AD, and that pancreatic expression of human amylin
in AD model rats accelerates behavioral deficits. Further, we tested effects of
lowering peripheral amylin and the suppression of amylin secretion in AD model
rats. We found that the amylin-related pathological processes are reduced by
pharmacological lowering amylin deposition in brain capillaries and amylin-Aβ
cross-seeding. Genetic suppression of amylin in AD model rats reduces amylinAβ cross-seeding and neurologic deficits.
Our data show evidence for a role of pancreatic amylin in AD and cerebral
microvascular pathology and suggest that drugs reducing amylin accumulation in
brain capillaries or preventing amylin from interacting with Aβ-associated
pathology could provide benefit in patients with AD. Therefore, targeting amylin
dyshomeostasis may be an effective strategy to prevent or slow the advancement
of Alzheimer and cerebrovascular disease.
KEYWORDS: Amylin, Alzheimer disease, cerebrovascular disease, type 2
diabetes, microvascular injury.
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CHAPTER 1. AMYLIN: FROM THE PANCREAS TO DEMENTIA
1.1. Introduction
Dementia is an important public health challenge that affects multiple
aspects of life. Alzheimer disease (AD) and cerebral vascular disease (CVD)
are common causes of impaired cognition and behavior in humans (1). The
development and progression of AD and CVD are complex and are affected by
metabolic risk factors, including type 2 diabetes (T2D). Although extensive
research studies have been conducted, the underlying molecular mechanisms
remain unclear. Research results from our laboratory and others have shown
that amylin, a satiation hormone that forms pancreatic amyloid in patients with
T2D, promotes small-vessel-type pathologies (2-4) and modulates amyloid
composition (2, 5-7) in both familial (genetically predisposed) and sporadic
forms of AD. Overexpression of human amylin in rodents (rodent amylin does
not form amyloid) leads to late-life onset T2D and neurological deficits (2, 8).
The results suggest amylin as a potential molecular modifier of the course of
AD and brain microvascular pathologies.
This chapter covers the overview of AD and CVD in relation to metabolic
risk factors, research studies on amylin, as well as the physiological and
pathological roles of amylin with emphasis on how amylin is recognized as a
link between pancreatic dysfunction and diabetic complications. This chapter
will also discuss the clinical evidence of amylin pathology in AD and CVD,
together with proposed disease mechanisms; to identify critical characteristics
of animal models that could help to better understand molecular mechanisms
underlying the increased risk of AD and CVD in patients with prediabetes or
T2D. Lastly, the scope of this dissertation is also included.
1.2. Alzheimer disease and cerebral vascular disease: discovery,
pathology and metabolic risk factors
1.2.a. Alzheimer disease
On November 4th, 1906, Dr. Alois Alzheimer gave an important lecture at
the Tübingen meeting that changed the medical view on dementia. He reported
a medical case of Auguste Deter, a 51-year-old woman patient, who had died
of an unusual mental illness. She was diagnosed with a progressive cognitive
disorder, focal symptoms, hallucinations, delusions, and psychological
incompetence. Dr. Alzheimer examined her brain autopsy and found
abnormally thin cerebral cortex with regions responsible for memory, language,
judgment, and thinking severely impaired. He noticed senile plaques (now
known as amyloid plaques) and tangles in nerve fibers (now known as
neurofibrillary/tau tangles) in the cerebral cortex (9). However, the scientific
community showed rejection toward his works, because there is a consensus
among medical doctors that dementia did not occur in patients younger than
70-year-old (senile dementia). In the published abstracts from the conference,
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only the title of Alzheimer’s lecture was presented with a statement in
parentheses that the lecture “was not appropriate for a short publication”. It was
not until 1907, Alzheimer published his lecture under the title “Über eine
eigenartige Erkrankung der Hirnrinde” (On an Unusual Illness of the Cerebral
Cortex) (10). Dr. Emil Kraepelin, the father of modern psychiatry, supported
and honored the works by Dr. Alzheimer by naming this peculiar disease after
Alzheimer in his famous Handbook of Psychiatry published in 1910. In 1911,
Dr. Alzheimer reported the second case of presenile dementia from patient
Johann F., who died at 57 years of age, and his brain showed “plagues-only”
without neurofibrils (11). Currently, both cases would be diagnosed as earlyonset Alzheimer dementia (presenile dementia). A recent study postulated that
Johann case was a form of genetically predisposed or familial AD (12).
AD patients suffer from progressive decline in memory, cognitive functions,
and psychosocial ability. Most of the AD cases occur on a sporadic basis.
Patients develop AD symptoms before age 65 are categorized under earlyonset AD (EOAD), which makes up about 5% of AD cases. Sporadic EOAD
shares a similar pathology profile with the “late-onset Alzheimer disease”
(LOAD), the most common form of the disease occurs after age 65. Although
the etiology of sporadic AD is unknown, 10-15% of EOAD cases are caused by
autosomal dominant mutations in three genes—amyloid precursor protein
(APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2), causing familial AD
(fAD). fAD symptoms develop earlier than sporadic AD, typically between 30
and 50 years of age, and progress quickly (13).
The cardinal features of Alzheimer pathology are the accumulation of
amyloid β (Aβ) and neurofibrillary tangles in the cerebral cortex (14). According
to the amyloid cascade hypothesis and the Tau hypothesis, the accumulation
of plaques and tangles triggers pathways to abnormal cellular metabolism and
neurodegeneration (14). Longitudinal community-based clinical-pathologic
study shows that probable AD, mild cognitive impairment (MCI), and amnestic
MCI, are pathologically heterogeneous disorders with mixed pathologies,
including vascular abnormalities, Lewy bodies (15, 16), and TAR DNA-binding
protein 43 (TDP-43) (17). Although nearly 90% of persons with clinically
probable AD met pathologic criteria for AD, mixed pathologies were as common
as “pure” AD pathology and are associated with the decline in cognitive function
(16).
1.2.b. Cerebral vascular disease
The term cerebral vascular disease (CVD) is used to refer to a group of
medical conditions that affect brain blood vessels and cerebral circulation.
Structural and functional changes in blood vessels cause vascular narrowing,
blockage, or rupture that affect oxygen and nutrient delivery to the brain (18).
As a result, stroke, transient ischemic attack, aneurysm, and vascular
malformation occur, leading to serious neurological complications and lifethreatening events.

2

Cerebrovascular pathologies contribute to vascular dementia (VD), which
made up at least 20% of cases of dementia, being second only to AD (19).
Various factors, including older age, hypertension, hypercholesterolemia,
diabetes, obesity, atherosclerosis, and cardiac diseases, have been shown to
enhance vascular risk and facilitate onset and progression of CVD-related
cognitive impairment (20, 21). Clinical-pathological studies shown that
concurrent CVD is an adjuvant to the expression of dementia caused by AD or
other neurodegenerative pathologies (19, 22, 23). Importantly, the severity of
small-vessel disease (visualized as white matter hyperintensities on magnetic
resonance imaging) contributes to the presentation of AD and predicts AD
conversion from mild cognitive impairment beyond Aβ status (24). Although it
is still not clear whether CVD is a concomitant pathology that is independent of
AD basic neuropathology (amyloid deposition and tauopathy) or one of the
triggers for AD expression, protecting cerebrovascular health can slow the
progression of cognitive impairment in aging individuals (20, 21).
1.2.c. Alzheimer disease, cerebral vascular disease, and diabetes
Clinical studies have found that dementia caused by CVD and AD are
associated with metabolic risk factors including T2D (25-31). Despite recent
advances in the care of patients with T2D, the risk of dementia remains higher
(up to 2-fold) in the population with T2D or prediabetes compared to
metabolically normal individuals (26, 27). The causative mechanisms
underlying diabetes-associated cognitive dysfunction and dementia remain
elusive. Clinical evidence indicates that overt hyperglycemia is linked to
diabetes-associated cognitive decline (32) and dementia risk in non-diabetic
individuals (33). However, multi-centered, randomized controlled studies have
shown that stringent control of glycemic parameters, i.e., glycated hemoglobin
(hemoglobin A1c) and fasting plasma glucose levels, does not improve
cognitive function (34, 35); rather, it increased mortality in patients with
dementia (35). Repeated hypoglycemic episodes are clearly linked to cognitive
decline and increased dementia risk (32, 36). From these studies, we foresee
a need to identify novel contributing factors to the risk of cognitive impairment
in humans with T2D or prediabetes.
Amylin, also known as islet amyloid polypeptide (IAPP), is a hormone
peptide co-synthesized with insulin by pancreatic β-cells and participates in
glucose homeostasis and the central regulation of satiation (37). Individuals
with prediabetic insulin resistance have hypersecretion of both insulin and
amylin (37). Thus, hyperamylinemia (high levels of amylin in the blood) always
coincides with hyperinsulinemia and prediabetic insulin resistance. Clinical
investigations found that human amylin, an amyloidogenic peptide, forms islet
amyloid in more than 90% of T2D patients (37-39). Studies from our lab first
show that amylin accumulates in the cerebral small vessels of patients with
dementia and T2D (2, 5). In brains of T2D patients with pathological AD, we
found amylin deposition and mixed amylin-β amyloid (Aβ) plaques (5, 6). These
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results are important because they suggest a novel pathological role of amylin
dyshomeostasis in the development and progression of AD and CVD.
1.3. The discovery of islet amyloid and amylin
The term “islet hyalinization” was initially used to describe islet amyloid in
the islets of Langerhans from diabetic patients when it was first independently
discovered by two researchers, Eugene L. Opie and Anton Weichselbaum (40,
41). When Opie found the hyaline materials in the pancreas, he could not
conclude on the amyloidosis of those hyaline materials because of inadequate
staining methods (40). For decades, abundant discussions and histological
studies took place on the nature of those hyaline deposits, which were often
thought to be connective tissue hyaline. It was assumed so until Nils Gellerstedt
and Jacques H. Ahronheim challenged the premise that the hyaline materials
frequently found in the pancreatic islets were connective tissue hyaline; rather,
based on its staining reaction and affinity for Congo-red, should be considered
amyloid (42, 43). In the 1960s, Ehrlich and Ratner confirmed that the Congo
Red-positive hyaline substance in the Langerhans islets was amyloidosis (44),
along with results from electron microscopy by Per Westermark suggested that
islet amyloid in human islets of Langerhans had fibrillary structure (45).
Summary of scientific discoveries is displayed in (Fig 1.1).
Islet amyloid deposits have greater insolubility compared with most other
amyloid forms (46), except for the amyloid core in Alzheimer disease’s plaques
(47). Hence, attempts to purify the major fibril protein in the islet amyloid was
hindered by its insolubility until formic acid was used to disintegrate amyloid
(48). Per Westermark and his colleagues extracted fibril protein from an
amyloid-rich insulinoma and characterized the protein by NH2-terminal amino
acid sequence analysis (48). They thought that this fibril protein might resemble
proinsulin, but this purification process revealed a novel peptide that has
significant sequence similarities to human calcitonin gene-related peptide (48)
(Fig. 1.2). The peptide was initially named “insulinoma amyloid peptide” by the
group (48). In 1987, Garth JS. Cooper successfully isolated this novel peptide
from the islet amyloid of T2D patients and showed it to be a 37-amino-acid
residue peptide (49) (Fig. 1.2). He named it “diabetes-associated peptide” (49).
It was finally named “islet amyloid polypeptide” (IAPP) (50) or “amylin” (51),
because it was found to be a normal secretory product, along with insulin, from
the pancreatic β-cells, not specific for diabetes (52, 53). This evidence suggests
that amylin might have physiological functions under normal conditions.
1.4. Amylin protein structure, protein expression and physiological
functions
1.4.a. Protein structure, processing and expression
Amylin is a 37-amino acid residue hormone peptide, synthesized, and cosecreted with insulin by pancreatic β-cells (53). The release of insulin and thus,
amylin from pancreatic β-cells is regulated by proopiomelanocortin neurons in
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the hypothalamus (54). In humans and rodents, plasma amylin levels rapidly
increase several-fold after meals (55). Amylin is expressed by one single-copy
gene on the short arm of chromosome 12, and it belongs to the calcitonin
peptide family, which includes calcitonin gene-related peptide, adrenomedullin,
and calcitonin. Amylin is derived from pre-pro-amylin, an 89-amino acid peptide
that contains 22-amino acid N-terminal signal peptide, and two short flanking
peptides (Fig. 1.3a). The signal peptide is removed in the endoplasmic
reticulum to produce a 67-amino acid pro-amylin. Pro-amylin contains cleavage
sites for prohormone convertase (PC) 2 and PC1/3, and the C-terminus is
cleaved by carboxypeptidase (CPE) during late Golgi process, exposing the
glycine residue for C-terminus amidation. The C-terminus is then amidated by
the peptidyl glycine α-amidating monooxygenase. An intramolecular disulfide
bond between amino acid residues 2-7, subsequently forms ring structure at
the N-terminus, producing mature amylin peptide (Fig. 1.3a). Pro-amylin is fully
converted to mature amylin in the β-cells secretory vesicles where insulin is
stored. The amylin concentration in the secretory granule ranges from ~500 μM
to 4mM. Amylin is co-secreted with insulin into the extracellular space within
the pancreatic islets; the peptide then diffuses into blood vessels and enters
the circulation (pM concentrations). (review in (37)).
Structurally, mature human amylin is relatively hydrophobic with several
positively charged residues: Lys-1, Arg-11, and His-18 (Figs. 1.3b-d). At or
below physiological pH, the peptide net charge ranges from +2 to +4, which is
important for interactions with negatively charged cell lipid membrane and
sulfated proteoglycans of the extracellular matrix (review in (56)). Normally,
human amylin is soluble and unfolded in its monomeric stage. Human amylin
forms insoluble amyloid when overexpressed (37). The amyloid formation by
human amylin is similar to that of other amyloidogenic proteins, where there
are three distinct phases: a lag phase, a growth phase, and a saturation phase.
Starting from the monomeric building blocks, amylin forms amyloid fibrils.
Based on time-resolved studies, it is now known that the soluble, low order
oligomeric intermediates are formed during the lag phase (57). The protein
conformation is an important feature in producing amylin toxicity effects
(discussed in section 1.5.a).
Reports show that amylin is found in other sites in the peripheral system, in
addition to the site of secretion. Amylin is found in pancreatic δ-cells of rat and
mouse (37), in the gastrointestinal tract of rat, mouse, cat, and human (58), and
the developing kidney (59). Amylin expression is also found in the primary
sensory neurons in dorsal root ganglia and the jugular-nodose and trigeminal
ganglion in rats (60). Mice with a null mutation in their rodent amylin gene had
reduced pain response without altered peripheral inflammation (61),
suggesting that amylin has a function in pro-nociceptive function in primary
sensory neurons (61). Additionally, amylin expression in the degenerative
human intervertebral disc (62) and varicella-zoster virus-infected human spinal
astrocytes (63) appear to play important roles in mediating the molecular
interaction and the pathology severity. In the central nervous system, amylin
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mRNA expression is below cutoff/not detected (in the brain tissues of rats and
humans) (8); rather, the source of amylin deposition in the brain is from the
periphery (64, 65).
1.4.b. Physiological functions
The physiological function of amylin and its mechanisms are not well
understood. Because it is co-secreted with insulin, amylin was hypothesized to
participate in glucose metabolism. Researchers have investigated amylin
functions in insulin secretion and insulin resistance, glucagon secretion,
glycogen synthesis in skeletal muscles, satiation, and gastric emptying (Fig.
1.4). Investigations on this matter in the animal and human systems have
generated interesting, yet, mixed results due to two main factors: lacking
appropriate experimental concentrations and unknown aggregation stage of
amylin, especially in the earlier studies done on amyloidogenic species of
amylin.
Insulin secretion and insulin resistance
Soon after amylin was discovered, ex vivo study showed the antagonistic
effects of amylin to insulin-stimulated glucose uptake and glycogenesis in rat
skeletal muscle (51); in vivo infusion of amylin in cats impaired glucose
tolerance (66). These studies generated hope that amylin was an underlying
mechanism for insulin resistance in T2D. However, experimental
concentrations for amylin in the above studies were higher than the
physiological
concentration,
placing
difficulty
to
separate
the
pathophysiological functions from the physiological ones. In contrast, the
administration of lower amylin concentration in rats did not affect glucosestimulated insulin secretion from the pancreatic islet, in vivo and in vitro (67).
Moreover, lower circulating amylin levels (~15 pM) in lean and non-diabetic
chronic kidney failure patients did not affect insulin secretion and did not cause
insulin resistance (68). Only at a very high plasma amylin level (about 90 times
normal postprandial peaks), amylin was found to decrease insulin secretion in
response to glucose (69). Notably, these studies did not consider the
aggregation stage of amylin, which is affected by high circulating amylin levels
and preparation/measuring methods in the experimental setting. It appears that
the high plasma amylin level accelerates amylin aggregation (amylin is an
amyloidogenic protein) and that amylin aggregation plays a role in decreasing
insulin secretion (through inducing β-cell apoptosis, will be discussed in section
1.5.a). From these studies, whether amylin plays a significant role in insulin
secretion and insulin sensitivity remains unclear and needs further
investigations.
Glycogen synthesis
Because it is plausible that circulating amylin affects insulin sensitivity,
amylin may affect insulin-stimulated glycogenesis in the skeletal muscles.
Results from several studies showed that synthetic human amylin inhibits
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insulin-stimulated rates of glucose incorporation into glycogen in both isolated
skeletal muscles and the diaphragm from fasted rats (55, 70).
Glucagon secretion
As part of the glycemic controlling factor, amylin is hypothesized as a potent
inhibitor of postprandial glucagon secretion. Limited data is available to support
this notion. During meals, glucagon secretion from the pancreatic α-cells is
stimulated by amino acids to mobilize amino acids to their storages in
peripheral tissues. Glucagon primarily acts on the liver to initiate glycogenolysis
and gluconeogenesis, leading to an increase in the endogenous production of
glucose. Thus, the inhibitory effect of amylin on glucagon secretion indirectly
controls blood glucose by suppressing endogenous glucose production (71).
This inhibition is extrinsic to the pancreatic islet, occurring only in intact animals
and humans, not in isolated islets or isolated perfused pancreas preparations
(71). The mechanism for these antagonistic effects remains elusive.
Regulation of satiation and gastric emptying
Although available evidence is scant, studies suggest that amylin regulates
satiation and inhibits gastric emptying via the central nervous system in animal
models and humans (72). Peripheral amylin normally crosses the blood-brain
barrier (64, 65) to bind to various regions in the central nervous system. Using
in vitro autoradiographic, investigators found high amylin binding areas,
including subfornical organ (circumventricular area), vascular organ of the
lamina terminalis, area postrema in the hindbrain, and the hypothalamus (55,
73, 74). Other high-moderate levels of binding areas include the thalamus (stria
terminalis) and mid-caudal nucleus accumbens (55, 73, 74). Evidence supports
the anorexic effect of peripheral amylin is mediated by direct humoral action on
the area postrema. Intraperitoneal injection and subcutaneous infusion of
amylin reduced food intake in rats (75, 76), whilst thermal ablation of the area
postrema significantly attenuated the anorexic effects of amylin delivered by
intraperitoneal injection in rats (77). On the other hand, blocking amylin
receptors with amylin antagonists increased food intake in rats (78). Although
it has been less-well investigated, amylin was also shown to lower body weight
in rats that were infused with rat amylin (79, 80). However, a recent study on
transgenic mice that overexpress [25, 28, 29triprolyl] human amylin, a laboratorygenerated non-amyloidogenic form of human amylin, showed a significant
increase in body weights of transgenic mice (81). Both centrally and
peripherally injected amylin appear to decrease the rate of gastric emptying
and intestinal transit (82, 83), therefore, controlling the nutrients/glucose from
entering the small intestine and subsequently into circulation. Specifically,
amylin seems to act through the central nervous system to inhibit gastric
emptying, as vagotomy in rats did not affect the ability of amylin to suppress
gastric emptying (84). Further studies on humans are necessary to elucidate
the mechanisms of amylin-induced satiation and gastric emptying.
1.5. The pathogenic role of human amylin on the islet β-cells
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Whether islet amyloid has pathogenic importance was an enigma. Islet
hyalinosis was initially found in association with diabetes, particularly in elderly
individuals, but not in all individuals with diabetes (44, 85, 86). Interestingly,
islet hyalinosis was also observed in nondiabetic individuals, especially in the
elderly, although not as extensive compared to diabetic individuals (43, 86, 87).
These observations seemed to dim the hypothesis that islet amyloid might be
a potential cause of T2D; rather, scientists proposed that islet amyloid is a
pathological response from the pancreas.
Despite the previous notion that islet amyloid formation was a pathological
response, later studies showed that amylin amyloid formation is important for
the pathogenesis of T2D. Pancreatic islet amyloid, in which amylin is the major
peptide component (37), is a common pathology in patients with T2D (40, 4244), and was reported in more than 90% of subjects with T2D (38, 39). A high
level of amylin in the blood, contributing to amylin aggregation, appears to
occur in patients with insulin resistance (88). Humans with a rare substitution
mutation in amylin (S20G, which increases amylin propensity to form amyloid
(89)) are associated with increased incidence or severity of T2D in the
Japanese population (90). Multiple mechanisms of human amylin-induced βcell toxicity have been proposed and tested. Those involve cellular membrane
disruption, oxidative stress, activation of the inflammasome, endoplasmic
reticulum stress, autophagy dysfunction, and the activation of cell death
signaling pathways, leading to the gradual loss of β-cell mass in T2D (38, 9194). Mechanisms relevant to this dissertation will be discussed in section 1.5.b.
1.5.a. The amyloidogenicity of human amylin is crucial for
cytotoxicity
Amylin from humans and several mammalian species including cats, dogs,
and monkeys (but not rodents) are amyloidogenic (37). The amyloidogenicity
of human amylin is central in amylin-mediated pathology in the pancreatic βcells (37, 91, 93, 95) and other organs (2-7, 96-99). The amyloidogenicity of
amylin in several species correlates with the fact that islet amyloid deposition
is species-specific, and is associated with the onset of diabetic syndrome in
humans and cats, but not in most rodents (100). Not all forms of aggregated
human amylin are cytotoxic to β-cells. Researchers previously assumed that
amylin mature fibrils were toxic to β-cells because it was commonly detected
near the islet cells (91, 101, 102). However, the recent data show that the
soluble oligomeric form, representing intermediate assemblies in the
aggregation process, exerts greater toxicity compared to the non-toxic mature
fibrillary form (57, 103, 104).
A specific region of human amylin is responsible for amyloid formation and
amyloid-mediated pathological functions. The 8-37 amino acid amylin variant,
which contains the amyloidogenic 20-29 amino acid sequence, is responsible
for the formation of the transient, parallel β-sheet structure during amyloid
formation in solution (105) (Fig. 1.3b, c). In rat amylin, the substitution for
proline residues in positions 25, 28, 29 of the amyloidogenic region disrupts the
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β-sheet secondary structure in this region. As the result, rat amylin oligomers
form α-helical secondary conformation (Fig. 1.3c), but the human amylin
oligomers form two stable conformations: an α-helical conformation with a short
β-sheet near the C-terminus (Fig. 1.3d), and a more stable full β-hairpin
conformation (106). When comparing similar-sized oligomers formed by human
amylin and rat amylin, studies found that the rat amylin oligomers are not toxic
to β-cells (57). The incubation of amyloidogenic 20-29 amino acid sequence
induces insulinoma cells apoptosis (100), whilst the substitution of three
prolines in the amyloidogenic region (rat amylin) abrogates the caspase
cascade activation and cellular apoptosis (92). Therefore, the differences in
oligomer conformational properties and/or their stability may well be an
important feature for enhancing toxicity by human amylin.
1.5.b. Mechanism of human amylin-induced toxicity in the
pancreas
Membrane disruption
The first mechanism of toxicity, and the most widely accepted one, is
membrane disruption and subsequent consequences of cellular homeostasis.
Initial observations by Westermark et al. (100) and Lorenzo et al. (91) provide
insight on the membrane disruption by human amylin causing cell death, and
the interaction of amylin with the cellular membrane is crucial for its toxicity,
respectively. Subsequent studies found that oligomeric human amylin can
directly incorporate into the plasma lipid bilayer and form membrane ion pores,
allowing the passage of molecules with the size of a calcium ion (107-110).
This results in membrane destabilization and leakage (107-111), as well as
disruption in islet architecture, which is critical for cell survival (112). The
process of fibril growth from the incorporated monomers or oligomers also
causes membrane damage (104, 107). In contrast, the monomeric and fibrillary
forms were not found to damage the cellular membrane (104, 107), although a
study showed that monomeric human amylin can destabilize the plasma
membrane by increasing its fluidity (113). Human amylin induces membrane
leakage in a much lower concentration than rat amylin, which is not
amyloidogenic (111). In addition to plasma membrane disruption, more
evidence suggests that aggregate human amylin can penetrate and may target
the mitochondrial and endoplasmic reticulum membranes, resulting in β-cell
mitochondrial dysfunction (114), endoplasmic reticulum stress and apoptosis
(115). However, there are issues with these proposed membrane disruption
mechanisms that they are not fully defined for the physiologically relevant
model, as the commonly used model membranes are very different from that
of the β-cell (111).
Oxidative stress, activation of inflammasome, and apoptosis pathways
The second mechanism of toxicity involves amylin-induced oxidative stress,
inflammation and apoptosis, which can be interrelated with cellular membrane
disturbance. Incubation of human amylin on rat insulinoma cells activated the
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apoptotic pathway involved caspase cascade activation (caspase-1 and -3 and
partially, caspase-8) (92). Islets from human amylin transgenic mice had
increased reactive oxygen species (ROS) levels and apoptosis in association
with amyloid deposition (116). A study on T2D human islets showed proinflammatory cytokine interleukin 1β (IL-1β) deposition in both macrophages
and extracellular space surrounding amylin-filled pancreatic islets (117). Colocalization of macrophage’s IL-1β and human amylin in pancreatic islet cells
was accompanied by a drop in insulin-producing cells (117). Mechanistically,
amyloidogenic human amylin, but not the non-amyloidogenic rat amylin, can
trigger NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3)
inflammasome activation and IL-1β production in bone-derived macrophages
and dendritic cells. Caspase-1 and NLRP3 are the mediators in human amylininduced IL-1β production, which eventually triggers apoptosis (117). Thus,
inhibition of amyloid formation by human amylin (92, 116), specifically,
inhibition of oligomer formation during the lag phase, rather than the fibril
formation in the growth phase (57), can prevent oxidative stress, inflammation,
and apoptosis in β-cells.
Endoplasmic reticulum (ER) and mitochondrial stress
Studies have reported ER stress and defects in ER-associated protein
degradation and unfolded protein response caused by human amylin (115, 118,
119). Defective protein folding machinery causes the accumulation of
misfolded and/or partially cleaved pro-amylin in the intracellular secretory
granules, which is postulated to be deleterious to β-cells (37).
Mitochondria from the β-cells of T2D patients show lower ATP levels,
impaired hyperpolarization of the mitochondrial membrane, and increased
density volume (120). Morphological and functional alteration of the
mitochondria indicates modification in oxygen sensing and oxygen metabolism.
Accumulation of human amylin oligomers in the ER causes a rise in cytosolic
calcium that leads to fragmentation of the mitochondrial network, slows down
mitochondria TCA cycle, and activates hypoxia signaling (121). This adaption
preserves β-cells survival in exchange for cell dysfunction (121).
1.6. Amylin accumulation and its effects on the extra-pancreatic tissues
(the heart and the kidney)
T2D increases risk for cardiovascular complications including heart and
kidney diseases, but the molecular link remains elusive. An early study on the
nature of the islet amyloid found a large number of hypertensive patient cases
was amyloid-positive, both diabetic and non-diabetic (43). Giving that amyloid
was found near the pancreas endothelial structure first, Ahronheim postulated
that amyloid interferes small blood vessels, resulting in increased blood
pressure, in a manner comparable to that leading to renal hypertension (43). A
later study by Ehrlich and Ratner (44) specifically showed Congo Red-positive
deposits between the capillary wall and islet cells. In contrast to findings by
Ahronheim, this study did not find a significant statistical correlation between
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the occurrence of amyloid and the degree of sclerosis of pancreatic arteries
and arterioles.
Interestingly, recent investigations from our lab and others report that
patients with T2D have an abnormal accumulation of aggregated amylin in
extra-pancreatic tissues, including the hearts (98, 122) and the kidneys (96,
97). In failing hearts of diabetic patients and human amylin expressing rats (HIP
rats), amylin accumulates in the heart blood vessel wall, perivascular space,
cardiac parenchyma, and cardiomyocyte sarcolemma (98, 122). Accumulation
of human amylin the kidneys of the HIP rats contributes to vascular injuries and
renal failure (97).
1.6.a. Mechanisms of human amylin-induced toxicity in the heart
and kidney tissues
Membrane disruption, oxidative stress, calcium dysregulation
Myocardial amylin incorporation destabilizes the sarcolemma membrane,
thus exposing the unsaturated fatty acids in the cellular membrane to cytosolic
ROS (123). This process triggers the formation of reactive aldehydes including
4-hydroxy-2-nonenal and malondialdehyde, which perturb intracellular
homeostasis and further leading to increased ROS and IL-1β production (98,
122, 123). Moreover, the ability of amylin oligomers to incorporate in the
sarcolemma causes Ca2+ leakage and Ca2+ dysfunction including elevated
cytosolic Ca2+ transients and activation of hypertrophic remodeling pathways
(98, 122, 124, 125). Using a transgenic rat model expressing human amylin
(HIP rat), studies found that high levels of blood amylin facilitate cardiomyocyte
remodeling (124), cardiac hypertrophy, and diastolic dysfunction (98, 122).
These alterations occur before the onset of overt hyperglycemia (prediabetes).
In contrast, prediabetic rats expressing nonamyloidogenic rat amylin display
normal heart structure and function (98, 122, 124).
Hypoxic-ischemic injury
Renal amylin deposition (in the glomeruli, interstitium, and blood vessels)
was found in ~48% of patients with diabetic nephropathy (96). Amylin
deposition was associated with a high level of plasma amylin and the severity
of renal tissue lesions and kidney dysfunction (96). Investigations from our lab
suggest that microcirculatory disturbances seen in the diabetic kidney tissue
are mediated by the accumulation of amylin in red blood cells and capillary
endothelium (97). Amylin accumulation consequently damages red blood cells
and endothelial cells, leading to tissue hypoxic-ischemic injury, and these
events take place before the onset of overt hyperglycemia (97). Therefore,
hyperamylinemia during the progression of T2D contributes to comorbidities,
including cardiovascular disease and chronic kidney disease, which are
commonly observed in diabetic patients (126).
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1.7. Amylin dyshomeostasis is a contributing factor for cerebrovascular
disease and Alzheimer disease
The postulated mechanisms linking T2D and dementia involve
cerebrovascular and noncerebral vascular ones (127, 128), in which amylin
infiltration from the circulation (as observed in hearts (98, 123, 124) and kidneys
(96, 97)) may be an important contributor to cerebrovascular injury and
neurodegeneration observed in demented humans.
1.7.a. Cerebrovascular mechanisms
Amylin infiltration from the periphery to the brain
Peripheral amylin can cross the blood-brain barrier to enter the brain
parenchyma, as demonstrated by early studies by Banks et al. (64, 65). The
studies found a significant amount of peripherally secreted amylin in the
interstitial fluid surrounding the cerebral cortex, and a small percentage of
amylin was associated with the capillaries (64, 65). This could represent one of
the transit routes for amylin from the periphery to the brain, although
alternatively, amylin could enter the brain through the leaky capillaries of the
choroid plexus. Banks and his colleagues postulated that amylin potentially had
a role in manifesting the effects of diabetes mellitus on the central nervous
system through the cerebrovasculature (64, 65). This hypothesis has been
proven to be true given the later supporting evidence.
Neurovascular unit injury
Mounting evidence indicates the presence of amylin deposition in the brains
of patients with T2D and dementia (2-7, 99, 129). Amylin accumulation is
abundant in the cerebral small vessels and is occasionally co-localized with Aβ
in cerebral amyloid of AD patients (2, 5) (Fig. 1.5). The severity of amylin
angiopathy increases in AD patients with T2D (2, 5). Areas with amylin
accumulation display altered vascular structure including enlargement of
perivascular space and disrupted vessel wall (2, 5). Our investigation first
showed that microvascular amylin accumulation is associated with infarction
and perivascular astrocyte recruitment, indicative of microvascular injury (2).
Specifically, amylin deposits were found in the neurovascular components (24, 129). We detected amylin accumulation in the endothelial cells (2), and these
deposits were associated with endothelial cell apoptosis (2). Schultz et al.
found that amylin formed intracellular inclusions in the brain microvascular
pericytes of AD patients with T2D (4). These amylin-containing pericytes
showed fragmented nuclei and loss of neuron-glial antigen 2 expression, which
is necessary for pericyte viability and function (4). Additionally, amylin appeared
to modulate pericyte autophagy and induced higher toxicity compared to Aβ
amyloid in vitro (4). Results from the same research team showed the presence
of aggregated amylin in the retinal microvessels of AD patients (3). Analysis of
capillary amylin accumulation in the retina appeared to correlate with
hippocampal amylin angiopathy and amylin burden (3). Other sites of amylin
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accumulation in the neurovascular unit such as astrocytes and microglia were
also detected in the brain of AD patients (129). These data suggest that the
brain blood vessels, as well as other components of the neurovascular unit, are
one of the sites of injuries caused by amylin accumulation.
Taken together, these results (2-6, 99, 129) infer the possibility of using
peripherally-mediated amylin dyshomeostasis as a biomarker of
cerebrovascular risk in patients with T2D.
1.7.b. Non-cerebrovascular mechanisms
Amylin-Aβ protein-protein interaction
One potential mechanism underlying diabetic contributions to dementia
involves the interaction of diabetes-related amylin dyshomeostasis with AD
pathology (Fig. 1.6). Our lab first identified elevated human amylin levels in the
brains of AD patients with or without T2D, and human amylin interacts with Aβ,
forming depositions in the brain parenchyma and brain blood vessels of those
patients (5) (Fig. 1.5). Similar results confirming our findings are later shown
by Fawver et al. and Oskarsson et al. (6, 7). Fawver et al. identified amylin in
the cerebrospinal fluid, brains of diabetic patients with vascular dementia or
AD, and non-diabetic patients with AD. Oskarsson et al. showed that the level
of amylin is increased in the diffuse and dense cerebral plaques and within
vascular amyloid deposits in the brains of patients with pathological AD, without
the clinical diagnosis of T2D (6). Interestingly, early in vitro evidence by
Kapurniotu’s group proposed that human amylin cross-assembly with Aβ
species (Aβ1-40 and Aβ1-42) inhibits the self-fibril formation by both amylin and
Aβ, thus stabilizing the oligomeric conformation (130, 131), which is later known
to be cytotoxic (57, 132). Additionally, the study by Fawver and colleagues
found human amylin augmenting Aβ oligomerization in the dose-dependent
manner (7). The results are consistent with later data showing that ex vivo
cross-seeding by amylin aggregates exponentially promote mixed amylin-Aβ
amyloid formation (6). In line with these findings, a recent investigation
demonstrated that mice expressing a mutated form of the amyloid precursor
protein (APP) (Tg2576) in neurons and human amylin in the pancreatic islets
developed mixed amylin-Aβ plaques in the brain (133), similar to the pathology
observed in individuals with T2D and AD (5-7). When compared to transgenic
mice expressing only the human amylin or the mutated form of APP protein
alone, mice with mixed amylin-Aβ pathology show accelerated neurological
dysfunction (133). The mechanism for exacerbated neurological function in this
mice model is postulated due to the increased Aβ burden in association with
elevated amylin accumulation in the brain (133). However, clinical data suggest
that patients with T2D and sporadic AD do not display augmented Aβ burden
(128, 134). Such contradictions can be explained. First, the transgenic mouse
model for AD over-expresses human Aβ, and along with aging, accumulating
senile plaques (fibrillary form) that are easy to detect by histological or
neuroimaging techniques. Second, amylin-Aβ cross-seeding does not
necessarily increase plagues formation in the context of “non-overexpressing
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Aβ” humans (sporadic AD), but the levels of toxic oligomers, which are not
readily detected in neuroimaging, may elevate. Third, T2D can worsen AD
outcomes by affecting the cerebrovasculature (29, 128, 135). Further
investigations are required to clarify the specific mechanisms in which amylin
dyshomeostasis interacts with AD pathology and exacerbates the progression
of AD.
The increased propensity of amylin and Aβ to interact may be due to the
fact that the amino acid sequence of human amylin is 52% similar to that of
Aβ1-40 and Aβ1-42. The studies mentioned above suggest the Aβ-seeding ability
of human amylin in the brain. Nonetheless, one cannot exclude that the Aβseeding for amylin deposition is also a possible process that may occur parallel
or independent from amylin-seeding Aβ.
In the brain of AD patients, amylin deposits co-localized with Tau and
abnormal forms of Tau in the hippocampal neurons (129). The co-localization
suggests that the area with amylin deposition is associated with neuronal
structural damage since normal forms of Tau maintain the dynamic of the
microtubule network (136).
Genetic interaction between amylin gene and AD pathophysiology
In addition to protein-protein interaction, intriguingly, amylin-Aβ interaction
is also found at the genetic level. Genome-wide association analysis further
supports the interaction between the amylin gene and AD pathophysiology
(137). Specifically, near genome-wide significant interaction effect was
observed for an imputed variant rs73069071, located on chromosome 12p
12.1, within the amylin gene (137). The rs73069071-by-Aβ deposition was
found for interaction effect on global cognitive function in AD patients (137).
Although remaining elusive, the postulated mechanism involves the effect of
this single nucleotide polymorphism on amylin production, whose product is
known to interact with Aβ or possibly altering Aβ metabolism, hence modulating
the impact of Aβ deposition on cognitive performance.
Amylin receptor-mediated cytotoxicity
Within the effort to understand the interaction of amylin and Aβ pathology,
several investigations suggest that the interaction is mediated through amylin
receptors (138, 139). Experimental data indicate that Aβ directly activates
amylin receptors and that the oligomerized Aβ-induced neurotoxicity can be
blocked with specific amylin receptor antagonists or downregulation of amylin
receptor expression (138, 139). Interestingly, amylin receptor expression in the
brain was up-regulated within the area of increased amyloid burden in AD
transgenic mice which overexpress the mutated form of APP (TgCRND8)
(139). Furthermore, amylin receptors inhibitor (AC253) can re-establish longterm potentiation in the hippocampus of AD mice (140). While amylin
accumulation appears to have deleterious effects, overexpression of amylin
receptor (by the unknown mechanisms) possibly provides a platform for Aβ14

induced neurotoxicity. Another study on primary rat hippocampal neurons
proposed that at low concentrations, the amylin receptor mediates neuronal
excitatory response (141). On the other hand, at high concentrations, human
amylin aggregates activate TRPV4 channels, triggering neuronal membrane
voltage-gated calcium channel opening, and membrane depolarization (141).
Amylin and amyloid precursor protein processing
Amylin and its analog, pramlintide, are shown to elevate Aβ production and
Aβ-related pathology in AD mice brains (142). The mechanism is through the
increased expression of γ-secretase, which participates in amyloid cleavage of
full-length amyloid protein precursor, in lipid rafts. However, the AD mice model
treated with amylin and pramlintide did not show a decline in long-term memory
tested by Morris water maze (142). Further studies employ other AD models
and sensitive tests for cognitive function are necessary to understand the
effects of amylin- or pramlintide-induced Aβ pathophysiology. In contrast, the
opposite results from several studies suggest that using human amylin and its
analog pramlintide could be beneficial for AD mice (143, 144). Nonetheless, it
is still not clear whether the lower concentration is required to prevent the
amyloid formation in those studies, and the problem with dosage control needs
more supporting data.
Mitochondrial dysfunction, calcium dysregulation, oxidative stress, and
inflammation
Besides the pathological interaction with Aβ and Tau, aggregated amylin
itself is neurotoxic because of its ability to 1) destabilize/damage the cellular
membrane, as discussed in section 1.5.a, and 2) possibly triggers deleterious
signaling pathways mediated by receptors, as discussed above. Several
mechanisms of amylin-induced neuronal toxicity, including mitochondrial
dysfunction, calcium dysregulation, and oxidative stress have been proposed
(99, 138, 145-149). A study by Estus and colleagues investigating the gene
expression pattern in human amylin-treated cortical neurons showed a total
decrease in mRNA synthesis from genes that are necessary for cell viability,
and the rate of neuronal death positively correlates with incubated amylin
concentration (150).
Human amylin shares a similar neurotoxicity profile with Aβ and other
amyloidogenic peptides. Both human amylin and Aβ trigger mitochondrial
dysfunction. Treatment of human amylin and Aβ on neuroblastoma cells were
shown to deregulate mitochondrial proteins, metabolism proteins, cell cycle,
and cytoskeleton-related proteins; thus, reducing mitochondrial functions and
eliciting abnormally high ROS generation (148, 149). Amylin-induced neuronal
death is mediated by increasing ROS production, following by elevated
intracellular Ca2+ with glutamate exposure (145). Removal of extracellular Ca2+
reduces Ca2+ influx, protecting cultured hippocampus neurons from human
amylin toxic effects (145). Pretreating neurons with antioxidants attenuates the
rise in intracellular Ca2+ and significantly preserves neuron survival (145),
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indicating that amylin first provokes the production of ROS, leading to a spike
in intracellular Ca2+. Interestingly, only the oligomeric form of amylin causes a
rapid increase in the cytosolic Ca2+ level, which triggers the Ca2+-dependent
apoptosis pathway (146). The mechanism of action for amylin mediated Ca2+
dysregulation is still not clear. Previous studies proposed that the mechanism
of elevated intracellular Ca2+ was resulting from extracellular Ca2+ influx
through calcium membrane channels and cation-channels formed by amyloid
peptides (146, 147). Some evidence suggests that amyloid oligomers may first
increase the cell membrane permeability, then penetrating into the cytoplasm
and causing leakage of stored intracellular Ca2+ (146). Despite the specific
pathway for Ca2+ entry or release, oligomeric amylin is capable of inducing
calcium dysregulation, confirming its toxic profile compared to the fibrillary form.
Our experiment on isolated rat neurons showed that human amylin forms
adduct with 4-hydroxynonenal, a marker of peroxidative membrane injury, and
leading to increased synthesis of IL-1β (99). The amylin-mediated neuronal
injuries (elevated levels of peroxidative product and IL-1β production) were
blocked ex vivo by membrane stabilizers and lipid peroxidation inhibitors (99).
Interestingly, soluble endogenous Aβ and human amylin are recognized by
CD36 (pattern recognition glycoprotein on macrophage surface), engulfed by
macrophage, and turned into oligomers/fibril amylin through intralysosomal
conversion, eventually leading to NLRP3 inflammasome activation and IL-1β
production (151). Thus, aggregated amylin deranges the lipid membrane and
predisposes it to calcium dysregulation and related apoptosis pathway,
peroxidative injury, and inflammatory responses.
Given the pathological function of aggregated amylin (2, 5, 8), the
interaction of amylin with Aβ may accentuate neurotoxicity. Therefore,
prevention strategies to effectively block amylin-mediated neurodegeneration
should involve the inhibition of amylin-induced neuronal membrane injury and
amylin-Aβ interaction.
1.8. Animal models to study contributions of T2D to cognitive impairment
and dementia
Rodents are the most commonly used laboratory models for diabetes and
dementia owing to their 99% similarity to the human genome (152). However,
neither diabetes nor dementia-like pathology spontaneously occurs in rodents.
Conditions associated with diabetes, dementia, or both can be induced in
rodents (2, 8, 153-155). For the most part, insights from these interventions
have been restricted to cerebral effects of inducing diabetes in normal rodents
and in rodents genetically modified to develop neurodegeneration linked to the
accumulation of Aβ in the brain. In humans with T2D, the variation in the clinical
phenotype of cognitive dysfunction or dementia may result from multiple
pathologies (25, 128). An existent challenge of using rodent models to uncover
mechanisms underlying the impact of T2D on brain structure and function lies
in the fact that some genetic modifications that lead to T2D phenotype directly
impact brain structure and function. For example, leptin or leptin-receptor
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deficiency, which is the commonly used genetic modification to induce obesityrelated metabolic disturbances in rodents (156), has negative effects on
learning and memory (157). Thus, interpretations made on specific molecular
mechanisms of diabetes-induced brain dysfunction need careful consideration.
Overexpression (3-fold) of human amylin in rats leads to the mid-life onset
of hyperglycemia linked to pancreatic amylin amyloid and β-cell apoptosis (95).
Diabetes in human amylin expressing rats (HIP rats) is associated with
neurological deficits including declined learning and memory, vestibulomotor
dysfunction, and gait abnormalities (2, 8). In brains of the HIP rats with motor
abnormalities, amylin accumulation is found in the brain parenchyma and blood
vessels (2, 8). Amylin deposition in small blood vessels correlates with
microhemorrhages, decreased tight-junction proteins levels, and perivascular
astrocyte activation (2), indicating that systemic amylin dyshomeostasis
damages the blood-brain barrier. Magnetic resonance imaging of HIP rat brains
showed increased ventricular volumes with white matter hyperintensities and
brain atrophy (2). Further assessment of cerebral blood flow in HIP rats
revealed that amylin dyshomeostasis was associated with capillary loss and
decreased cerebral perfusion (2). Amylin dyshomeostasis occludes or/and
damages the brain small vessels, leading to brain parenchymal loss.
The metabolic consequences of amylin dyshomeostasis have been
observed in the HIP rat heart, brain, liver, and plasma using non-targeted
metabolomics analysis (158). In HIP rat brains, there is a 50% reduction in
tyrosine and phenylalanine (precursor for tyrosine), which is significant
because tyrosine and phenylalanine are precursors of catecholamine
neurotransmitters (dopamine, norepinephrine, and epinephrine) (158). Also,
HIP rat brains have significantly altered pentose phosphate pathway that is
preferentially used by neurons to metabolize glucose and maintain their antioxidant status) (158). Altered pentose phosphate pathway is commonly seen
in neurodegenerative diseases (159). Importantly, these metabolic
consequences are not characteristic of diabetes (158), but uniquely related to
the amylin-driven pathology in the amylin dyshomeostasis rat model. Both the
reduction in the levels of neurotransmitter precursors and alteration in pentose
phosphate pathway correlate with the neurological dysfunction in HIP rats (2,
8). Therefore, the animal model with amylin dyshomeostasis has the advantage
of recapitulating vascular injury, brain atrophy, and metabolic changes seen in
the brains of individuals with T2D and neurodegenerative diseases (for reviews
(128, 159)).
1.9. The future of brain amylin research
Till today, there remains much of what we wish to know about this peptide.
However, current encouraging investigations have allowed us to gain a better
understanding of the basic mechanisms of amylin-mediated physiological
processes and pathologies. Along with robust technology development during
these past decades (genetically engineered non-human vertebrates and nonvertebrate models, advance imaging techniques, next-generation sequencing,
17

bioinformatics, etc.), useful tools will be used to decipher the role of amylin
dyshomeostasis in the early pathological progression of AD and CVD, and
hopefully, the results can be translated to the characterization of the biomarkers
for early diagnosis of dementia and therapeutic interventions.
1.10.Scope of dissertation
1.10.a. The role of amylin dyshomeostasis in CVD: cerebral
microvascular injury and brain white matter disease
The general hypothesis tested is that aggregated amylin circulates through
the blood, deposits in brain blood vessels and provokes brain microvascular
injury by degrading endothelial cell coverage and tight junctions.
Specific aim 1: To test this hypothesis, we performed in vivo phenotyping
of rats expressing amyloidogenic human amylin in the pancreas (HIP rats) and
generated amylin knockout rats that were intravenously infused with
aggregated human amylin.
Specific aim 2: To test this hypothesis, we also carried out biochemical
analyses of brain tissues from humans and studied the effects of the
aggregated amylin on endothelial cells, ex vivo.
1.10.b. The role of amylin dyshomeostasis in the development of
AD and progression of the disease
The general hypothesis tested here is that amylin dyshomeostasis
exacerbates AD pathology and disease progression by modulating the amyloid
composition and vascular injuries in both familial and sporadic forms of AD.
Specific aim 1: To test the potential relationship between pancreatic
amylin, the brain and familial AD, we analyzed brain tissues from fAD patients
for amylin deposition and interaction with areas of AD-related histopathology.
Brains from sporadic AD was also used to assess the amylin pathology and
interaction with Aβ.
Specific aim 2: To assess the consequences of amylin pathology seen in
human brains, we generated transgenic AD and non-AD rat models in which
the consequences of elevated blood levels of human amylin can be directly
addressed in terms of AD pathology and neurological deficits. To further test
the mechanism, we intravenously injected human amylin in AD rats that
express non-amyloidogenic rat amylin; and assessed amylin-mediated
pathology without confounders due to the development of amylin
dyshomeostasis.
Specific aim 3: To test whether lowering blood amylin ameliorates the
disease pathology and progression, we generated AD rats with the amylin gene
deleted to test effects of suppression of amylin secretion on AD pathology and
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dyshomeostasis in aged ADHIP rats.
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FIGURES

Figure 1.1. Timeline for amylin-related research publications with highlights
in major discoveries. PubMed searches were performed using the “IAPP” (islet
amyloid polypeptide) or “Amylin” keywords for the number of publications per year.
The discovery of insulin is also included in the highlights due to its important role
to the study of glycemic-regulating hormones secreted from the pancreatic β-cells.
This consequentially leads to the study of islet dysfunction, islet amyloid and
amylin.
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Figure 1.2. Amino acid sequences of human amylin and human calcitonin
gene related peptide (CGRP). Human amylin has significant sequence
similarities to human CGRP.
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Figure 1.3. Schematic of amylin protein processing and structural
differences between human and rat amylin peptides. (a) The amino acid
sequence of human pre-pro-amylin (89-amino acid residues) with the cleavage
sites for prohormone convertase (PC) 2, PC1/3, and carboxypeptidase (CPE).
After being cleaved by PCs, CPE then removes the KR residues, exposing the
glycine residue (blue) used for C-terminus amidation by the peptidyl glycine αamidating monooxygenase. Mature human amylin contains 37-amino acid
residues with amidated C-terminus and intramolecular S-S bond between residues
2–7 at the N-terminus (ring structure). (b) Structural differences between
amyloidogenic human amylin vs. non-amyloidogenic rat amylin. In rat, the
substitution for proline residues in positions 25, 28, 29 of the amyloidogenic region
(20-29) inhibits the amyloid formation. (c) Cartoon diagram of rat amylin in helical
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form, colored in rainbow spectrum with N-terminal ring structure in blue. Helix
spanning residues are A5-S23. Substituted residues from human amylin colored
in orange and pale blue sticks: R18, L23, P25, V26, P28, and P29. Three prolines
(prevent amyloid formation) in rat amylin are highlighted in pale blue sticks. (d)
Cartoon diagram of human amylin in helical form, colored in rainbow spectrum with
N-terminal ring structure in blue. Helix spanning residues are A5-S28. Residues
on human amylin that are different from rat amylin are colored in purple sticks:
H18, F23, A25, I26, S28, and S29. Cartoon diagrams were constructed using
PyMol.
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Figure 1.4. Schematic summary of amylin physiological functions. Amylin
possibly inhibits insulin secretion and participates insulin resistance. Amylin may
inhibit glucagon secretion and insulin-stimulated glycogen synthesis in the skeletal
muscles. Amylin regulates satiety and possibly slows gastric emptying via the
central nervous system.
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Fig. 1.5. First reports from our laboratory on amylin accumulation in the
brains of AD patients. (a-d) Representative immunohistological images of
vascular amylin deposits (a) and vascular amylin-Aβ interaction (b-d) in the brains
of T2D patients with sporadic AD (T2D-D) (b, d) and cognitively unimpaired nondiabetic individuals (Controls; Ctl) (c). (e) Analysis of amylin angiopathy in Ctl,
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T2D-D, and AD, assessed from immunohistological staining. (f, g) Representative
immunohistological images of amylin plaques (f) and amylin-Aβ mixed plaques (g)
in the brains of T2D-D. (h) Analysis of amylin-Aβ mixed plaques in the brains of
T2D-D vs. AD, assessed from immunohistological staining. (i, j) Representative
immunohistological images of intraneuronal amylin accumulation (i) and
intraneuronal amylin and Aβ plaques (j) in the brains of T2D-D. Data are mean ±
SEM; P ≤ 0.05 *, P ≤ 0.01 **; two-tailed, unpaired t test. Figures are adapted from
previous publications of Jackson et al. (2013) and Verma et al. (2016).
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Fig. 1.6. Diabetes-related amylin dyshomeostasis leads to the formation of
pancreatic amyloid and promotes amylin accumulation in the brain
microvasculature. Circulating oligomerized amylin deposits in the brain
microvasculature and induces small vessels injury by deranging the microvascular
endothelium. Oligomerized amylin also forms mixed amylin-Aβ plaques in the brain
parenchyma, accentuating neurotoxicity. Diabetes related amylin dyshomeostasis
promotes a feed-forward pathological process by which circulating oligomerized
amylin injures brain microvasculature and synergizes with Aβ pathology to induce
dementia.

27

CHAPTER 2. BRAIN MICROVASCULAR INJURY AND WHITE MATTER
DISEASE PROVOKED BY DIABETES-ASSOCIATED HYPERAMYLINEMIA
2.1. Introduction
Microvascular-related brain injury is associated with focal neurologic deficits
and dementia (18, 160-163). The distal territories of small penetrating vessels
(arterioles and capillaries) supplying brain white matter are particularly
vulnerable to vascular pathologies (also known as cerebral small vessel
disease). High blood pressure, atherosclerosis and inflammation are among
the major causes of brain white matter disease of vascular origin (18, 160-163).
Recent investigations (4-6) have revealed that the brain microvasculature of
patients with dementia contains large deposits of amylin, a ~4 kDa peptide cosynthesized with insulin by pancreatic β-cells (37). Vascular deposition of
amylin is particularly abundant in the brains of patients with dementia and type
2 diabetes (5, 6). The peptide amylin (or islet amyloid polypeptide) normally
crosses the blood brain barrier (64) and binds to neurons in the feeding centers
(164, 165), where it is believed to induce an anorexic effect (55, 166). In
patients with type 2 diabetes, amylin forms amyloid in the pancreatic islets that
triggers β-cell apoptosis (37, 93, 119). Deposits of aggregated amylin are also
identified in failing hearts (98, 123) and kidneys (96) of individuals with type 2
diabetes or obesity. Of note, apolipoprotein E4 (APOE4), which is strongly
associated with β amyloid (Aβ) pathology (167, 168), modulates amylin
aggregation (169) and amylin amyloid formation (170, 171).
Amylin from species that do not develop type 2 diabetes (i.e. mice and rats)
is non-amyloidogenic due to proline substitutions at the 25, 28, and 29 sites
(100). Pharmacological induction of insulin resistance in transgenic mice
expressing the amyloidogenic amylin variant (i.e., human amylin) caused intraand extracellular amylin amyloid deposition, β-cell apoptosis and overt
hyperglycemia (172). Similar pathologic changes occur in rodents
overexpressing human (95), but not murine amylin (119). We previously
reported that rats overexpressing human amylin in the pancreas accumulate
aggregated amylin in the brain (8), which correlates with the development of
neuroinflammation (8, 99), reduced synthesis (by >50%) of catecholamine
precursors (phenylalanine and tyrosine) (158) and neurologic deficits (8).
Furthermore, a recent study demonstrated that transgenic mice overexpressing
human amylin in pancreatic islets and a mutant form of the amyloid precursor
protein (APP) in neurons have exacerbated Aβ pathology compared to
transgenic mice expressing only one or the other protein (133).
Distinct from other diabetic complications, glucose dysregulation does not
appear to be the primary determinant of progressive brain injury in patients with
diabetes (25, 26, 29, 173-175). The pathophysiology underlying slowly
progressive functional and structural brain changes in the setting of type 2
diabetes is largely unknown (25, 26, 29, 173-175). Given the toxicity of
aggregated amylin (37, 93, 96, 98, 119, 123), we hypothesized that the
complex pathophysiology (25, 26, 29, 173-175) underlying slowly progressive
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functional and structural brain changes in patients with type 2 diabetes involves
accumulation of aggregated amylin in the brain blood vessels. Here, we tested
the hypothesis that aggregated amylin circulates through the blood, deposits in
brain blood vessels (possibly via the interaction with plasma apolipoproteins)
and provokes brain microvascular injury by degrading endothelial cell coverage
and tight junctions. To test this hypothesis, we performed in vivo phenotyping
of rats expressing amyloidogenic (human) amylin in the pancreas (HIP rats
(95)) and generated amylin knockout (AKO) rats that were intravenously
infused with aggregated human amylin. We also carried out biochemical
analyses of brain tissues from humans and studied the effects of the
aggregated amylin on endothelial cells, ex vivo. Our findings may contribute to
the understanding of the complex molecular mechanisms underlying the
diabetes-associated stroke and dementia (25, 26, 29, 173-175).
2.2. Materials and methods
This investigation conforms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publication No.
85-23, revised 1996) and was approved by the Institutional Animal Care and
Use Committees at University of Kentucky.
Paraffin embedded brain tissues were provided by the Alzheimer Disease
Center biobank at the University of Kentucky. The protocol was approved by
the Institutional Review Board.
For immunohistochemistry, formalin fixed dorsolateral frontal cortex
(Brodmann area 9) tissue was used from three autopsied individuals >80 years
of age at death, with type 2 diabetes and dementia and three age-matched
cognitively normal individuals without type 2 diabetes (Table 2.1). The
absence/presence of diabetes was determined during life (at longitudinal
clinical visits) by patient or caregiver self-report and the use of diabetic
medications (176). The assessment of clinical dementia and the
neuropathologic features - neuritic amyloid plaques (Consortium to Establish a
Registry for Alzheimer’s disease; CERAD), Braak NFT stage and cerebral
amyloid angiopathy (CAA) severity - were scored as previously described (177181). Neuropathological information, APOE genotype, age and sex of each
individual included in the present study are summarized with specific findings
related to the vascular amylin pathology.
2.2.a. Experimental animals
HIP rats (n = 79; breeding pairs provided by Charles River Laboratory,
Wilmington, MA) were used in behavior testing and physiological analyses. HIP
rats are Sprague-Dawley rats that overexpress (3-fold) human amylin in the
pancreatic β-cells (95). Wild-type (WT) littermate rats (n = 49) were used as
non-diabetic controls.
AKO rats were used to identify a possible interaction of amylin with plasma
apolipoproteins (APOE) and to test whether intravenous infusion of aggregated
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human amylin injures the brain microvessels independently of glucotoxicity.
AKO rats (rather than WT rats) were used in amylin-injection experiments to
eliminate the confound that rodent amylin and human amylin form mixed
oligomers (182). AKO rats were generated in collaboration with Transposagen
Biopharmaceuticals (Lexington, KY). The rat amylin gene was targeted at two
sites by producing double strand breaks in the genome using the
CRISPR/CAS9 system (183). The CRISPR gRNAs and Cas9 mRNA were
microinjected into the pronucleus of fertilized Sprague-Dawley rat embryos by
standard techniques, and the embryos were re-implanted to produce the
genetically modified offspring. Amylin gene knock-out was confirmed by
genotyping using the following primers for DNA amplification: Forward: 3’AGAGCTAAGCAAGTTGAGGGAT-5’;
reverse:
ACCACTAGTTCACATTCACAGAGG. AKO rat pancreas was tested for amylin
immunoreactivity signal by Western blot.
2.2.b. Behavior testing
Inclined Plane
Rats were placed on the flat plane in the horizontal position with head facing
either up or down to the side to be raised. Starting at 30o, the angle was
increased at 2o/second. The angle at which the animal starts to free-fall was
recorded. Each rat received 3 trials per head facing direction. Rats were
allowed to rest 1 minute between trials. Results were averaged for 6 trials.
Cylinder Test/Forelimb Use Test
To evaluate forelimb deficits, the animal was placed in a transparent
cylinder for 5 minutes, and the activity was video recorded. The time that
forepaws contacted with the cylinder wall during vertical rearing up was
calculated using slow-motion playback software (Kinovea).
Morris water maze
Visuospatial learning and memory retention was tested in a 1.5 m diameter
Morris water maze (184). HIP and WT littermate rats with no motor impairments
were given 10 learning trials per day for two consecutive days using random
starting locations (N, E, S, W). Animals were allowed to stand on the platform
for 30 seconds after the first trial and 15 seconds after each additional trial. If
the animals failed to locate the platform, they were picked up and put on the
platform for 15 seconds. To assess reference memory, a probe trial was given
24 hours after the second acquisition day. The probe trial was scored on
latency to cross the platform. Trials were recorded by EthoVision XT software
(Noldus, VA).
2.2.c. Magnetic resonance imaging
MRI data were acquired using a horizontal 7T nuclear magnetic resonance
scanner (ClinScan, Bruker BioSpin MRI, Ettlingen, Germany) and a 38-mm rat
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brain coil. Rats were first anesthetized with isoflurane (4.0% for induction, 1.2%
for maintenance) and air mixture. Heart rate (90 to 130 b.p.m.), respiration rate,
and rectal temperature (37 ± 0.5oC) were continuously monitored. Heart rate
and blood oxygen saturation level were maintained within normal physiological
ranges. Coronal T2-weighted MR images were obtained using the following
variables: repetition time, 3000 milliseconds; echo time, 24 milliseconds; field
of view, 40 mm; thickness, 1mm, 7 slices. Ventricular volume was measured
from the frontal horn of lateral ventricle to the foramen of Luschka by combining
hyperintensity ventricular area using ImageJ over all slices and multiplying by
section thickness (185). Similarly, total brain volume was measured by
multiplying combined brain area over all slices to section thickness.
Parenchymal volume was calculated by subtracting ventricular volume from
total brain volume.
2.2.d. Isolation of rat brain capillaries
Freshly isolated brain was homogenized in capillary PBS (cPBS) (137 mM
NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.47 mM KH2PO4, 1.05 mM MgCl2, 0.9
mM CaCl2, 5 mM glucose, 0.9 mM sodium pyruvate). To separate blood
vessels from brain parenchyma, the brain homogenate was centrifuged in 30%
Ficoll PM 400 solution (F-4375, Sigma, MO) at 5000 xg for 20 minutes, 4oC.
The capillaries were then isolated by the glass bead column filtration method.
In the first step, the pellet resulting from the centrifugation was re-suspended
with 1% BSA in cPBS and passed through a 300 µm strainer. Then, the filtered
pellet suspension was added into the glass bead column. Two hundred
milliliters of 1% BSA was passed through the column. Capillaries were retrieved
from the beads by agitation in 1% BSA and filtering through a strainer, followed
by centrifugation at 500 xg for 5 minutes, 4oC. Capillaries were washed twice
with cPBS before the experiment. For quality control, capillaries were stained
with Texas red dye and were examined under confocal microscope.
2.2.e. Cerebral blood flow measurement
Fluorescent microspheres (15 μm diameter; F8839, Thermo Fisher, MA)
were vortexed for 30 seconds in heparinized saline (106/mL fluorescent
microspheres). Anesthetized HIP and WT rats were injected with a 200 µl
volume containing microspheres and heparinized saline through the jugular
line, twice (15 mins apart). Animals were sacrificed, and the brains collected
for tissue digestion, capillary isolation (as described above) and microsphere
recovery by filtration followed by fluorescence measurements.
Equal weights of brain capillaries and remaining parenchymal tissue from
WT and HIP rats were individually digested in 4M KOH and 2% tween 80
(Sigma Aldrich, MO). The tissue was completely digested within 24 hours. The
digested tissue was then filtered through 10μm pore polycarbonate filters
(Millipore, CA). The vial and filtering syringe were washed twice with 2% tween,
and wash was filtered to recover residual microspheres. The filter and filtered
material from each tissue were placed in 1.25 ml of Cellosolve acetate (Sigma
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Aldrich, MO) in tubes. After ≥4 and up to 24 hours, 100µl samples from each
tube were placed in a 96 well microplate and the fluorescence of each was
determined by fluorescent spectrophotometer.
2.2.f. Histology
HIP, WT and AKO rat brains were analyzed by staining with Prussian blue
and Luxol fast blue (LFB). For Prussian blue staining, sections were
microwaved in solution containing 5% HCl and 5% potassium ferrocyanide
(14459-95-1, Acros, Geel, Belgium). Nuclei were stained with neutral red
(N7005, Sigma, MO). For LFB staining, sections were treated with LFB
(AC212170250, Acros, Geel, Belgium) solution overnight (O/N) at 56oC,
followed by 95% ethanol and dH2O rinse. Slides were differentiated in lithium
carbonate solution then 70% ethanol, followed by hematoxylin and eosin (H&E)
staining (BP2424-25, E511-100, Fisher, PA). Images were obtained on the
Nikon Eclipse 55i upright microscope (Nikon, Tokyo, Japan).
2.2.g. Immunohistochemistry
We used brain tissues from humans, HIP, WT and AKO rats. Tissues were
processed as previously described (5, 99). Antibodies against amylin (1:200,
T-4157, Bachem-Peninsula Laboratories, San Carlos, CA), glial fibrillary acidic
protein (GFAP; 1:600, MAB360, Millipore, MA) or myelin basic protein (MBP;
1:5,000, AMAB91064, clone CL2829, Sigma, MO) were the primary antibodies.
Anti-mouse or anti-rabbit IgG (1:50, A3562, A3687, Sigma, MO) were
secondary antibodies. The specificity of the amylin antibody in both human and
rat brain tissues was established in previous studies (5, 6, 99).
2.2.h. Demyelination scoring
Demyelination of the white matter (MBP and LFB staining) was scored by a
blinded observer. Ordinal pathologic scoring was used, ranging from normal to
severe demyelination (0-3) (186).
2.2.i. Immunofluorescence
We used brain tissues from humans, HIP, WT and AKO rats, and isolated
brain capillaries from HIP, WT and AKO rats. Brain tissue was processed as
previously (99) described. Brain capillaries were isolated (as described above)
and then plated on laminin (23017-015; Gibco, Waltham, MA)-coated
chambered cover glass for 1-hour, to allow time to attach.
Antibodies against human amylin (1:200, SC-377530; Santa Cruz, TX),
collagen IV (1:500, SAB4200500; Sigma, MO), caveolin1 (1:1,000, sc-894;
Santa Cruz, TX) and APOE (1:200, ab183597; Abcam, MA) were the primary
antibodies. Alexa Fluor 488-conjugated anti-mouse IgG (A11029, Invitrogen,
MA) and Alexa Fluor 568-conjugated antirabbit IgG (A11036, Invitrogen, MA)
were the secondary antibodies.
2.2.j. Immunoprecipitation
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HIP rat plasma was investigated in these experiments. Protein
concentration was determined by bicinchoninic acid protein assay prior to
immunoprecipitation. APOE was precipitated from 700 µg plasma protein.
Samples were incubated at 4oC O/N with 5 µg anti-APOE antibody (ab183597,
Abcam, MA) or anti-APOA-1 antibody (H00000335-D01P; Abnova, Taipei,
Taiwan). Antibody-antigen complex was precipitated out by protein A/G
agarose (20421, Thermo Scientific), rotated for 3 hours at 4oC.
Immunoprecipitates were collected by centrifugation followed by washing three
times with buffer (5 mM ethyleneglycoltertraacetic acid [EGTA], 50 mM Tris,
1% Triton X-100, phosphatase and protease inhibitors 1:100 ratio, pH 7.5).
Proteins were eluted two times with elution buffer (0.2 M glycine, 80 mM HCl,
pH 2) and incubated on ice for 5 minutes with the supernatant collected by
centrifugation. Centrifugation speed was 1000 xg for 1 min at 4oC. Samples
were resuspended in loading buffer and subjected to Western blotting.
2.2.k. Western blot analysis
Western blot analysis was performed on isolated brain capillaries from rats
and plasma and whole blood lysates from rats and humans. Plasma and whole
blood were processed as described previously (5, 123). Capillaries were
isolated as described above and then lysed in buffer containing 1% NP-40,
150mM NaCl, 10mM Tris-HCl, 2mM EGTA, 50mM NaF, 1% phosphatase and
1% protease inhibitors. The lysate was centrifuged at 17,000 xg for 30 minutes.
The supernatant was used for Western blotting. Primary antibodies against
amylin (1:2,000, T-4157, Bachem-Peninsula Laboratories), occludin (1:300,
71-1500, Invitrogen), claudin-5 (1:1,000, 35-2500, Invitrogen), ZO-1 (1:300, 617300, Invitrogen), collagen IV (1:1,000, ab6586, Abcam), caveolin1 (1:1,000,
sc-894, Santa Cruz Biotechnology) or β-actin (1:10,000, PIMA515739, Fisher
Scientific) were used in these analyses. Equal loading in Western blot
experiments was verified by reprobing with a monoclonal anti-β-actin antibody
(raised in mouse, clone BA3R, Thermo Scientific; 1:2000). Protein levels were
compared by densitometric analysis using ImageJ software.
2.2.l. Real-time quantitative reverse transcription polymerase
chain reaction
Expression levels of caveolin-1 and collagen IV in rat brain capillaries were
measured using a protocol described previously (99). Caveolin-1 primers
(forward,
5’-CTTAAATCACAGCCCAGGGAAAC-3’;
reverse,
5’GCGTCGTACACTTGCTTCTC-3’) and collagen IV primers (forward, 5’AAATGGCGCTCCTGATCCAA-3’,
reverse:
5’TTCTTGTGGAGTTCTCGCCC-3’) were used in these experiments. Actin
primers (forward, 5’-CTGGCTCCTAGCACCATGAA-3’ and reverse, 5’AAAACGCAGCTCAGTAACAGTC-3’) were used as internal controls.
2.2.m. Cell culture and flow cytometry analysis
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Prior to plating, culture flasks were coated with cell attachment factor
solution (123-100, Sigma). Brain microvascular endothelial cells from WT adult
Sprague Dawley rats (RA-6023, Cell Biologics, Chicago, IL) were plated for 24
hours and used for experiment when they reached 70% to 90% confluency.
Cells were incubated with 50 μM human amylin (AS-60804, AnaSpec, Fremont,
CA) for 2 hours at 370C. Cells were dissociated with trypsin and washed with
cold PBS before being stained with propium iodide (PI) and Annexin V (AnV),
according to manufacture protocol (V13241, Life Technologies, Waltham, MA).
Apoptotic cells and necrotic cells were detected with analytical flow cytometer
(LSRII; Becton Dickinson, Franklin Lakes, NJ).
2.2.n. Statistical analysis
Parametric comparison of 2 groups was done using 2-tailed unpaired t test.
Non-parametric comparison of 2 groups was done using Mann–Whitney
unpaired t test. Two-ways analysis of variance (ANOVA) with repeated
measures followed by Bonferroni post hoc tests were used to analyze the
Morris water maze data. Data are presented as means + standard error of the
mean. Difference between groups was considered significant when p < 0.05.
All analyses were performed using GraphPad (LA Jolla, CA) Prism 5.0
software.
2.3. Results
2.3.a. Impaired neurological functioning upon inducing amylin
dyshomeostasis in rats
Both male and female HIP rats had increased plasma levels of amylin and
developed overt hyperglycemia (>200 mg/dl; nonfasted; Fig. 2.1). Western blot
analysis of amylin in plasma samples showed multiple molecular weight bands
(higher amylin immune-reactive signal was seen in HIP rats compared to WT
rats). The higher molecular weight bands could correspond to circulating amylin
aggregates, as suggested by previously published data(8, 122, 123), or amylin
binding to plasma components (including plasma APOE; see below).
In contrast to WT littermate rats that had normal behavior, HIP rats had gait
abnormalities and impaired balance (Supplementary Videos 1 and 2),
spontaneous forelimb use, hind limb clasping, and altered balance on a
stationary inclined plane (Fig. 2.1c-e). HIP rats and WT controls had similar
swim speeds; however, latency to platform over the 20 learning trials was
longer for HIP rats compared to WT littermates (p = 0.03), indicating that HIP
rats had impaired learning. Reference memory, defined as the latency to cross
the platform at 24 hours after the second acquisition day (probe trial), was
similar for HIP and WT rats, indicating no significant memory deficits associated
with amylin dyshomeostasis once the task had been learned. Compared to
males, female HIP rats developed hyperglycemia and neurologic deficits
(Supplementary Videos 1 and 2) later in life (ie, ~12 months vs ~18 months
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of age). Balance and gait abnormalities were milder in females compared to
male HIP rats.
2.3.b. Brain white matter injury in HIP rats
Based on in vivo MRI (T2-weighted sequences), the brains of HIP rats had
structural abnormalities, which were not present in control WT littermates (Fig.
2.2a). Compared to controls, brains of diabetic male HIP rats showed areas of
high T2 signal in the lateral hippocampus and around the temporal horns of the
lateral ventricles and expansion of the ventricles (Fig. 2.2b). Expansion of the
ventricles and the high T2 signal in the surrounding tissue may reflect defects
in the resorption of cerebrospinal fluid or/and subcortical atrophy. Because the
current MRI protocol only included coronal T2 images, we cannot formally
distinguish between these possibilities.
The volume of brain parenchyma was smaller in diabetic animals compared
to controls (Fig. 2.2c). Injured ependyma and amylin deposition in choroid
plexus were found in HIP rats with considerably enlarged ventricles (Fig. 2.2d,
e). The brains of rats with falls and impaired balance often revealed
intracerebral hemorrhages (Fig. 2.2f, arrow), which were not found in control
WT littermates.
We used the fluorescent microsphere technique to assess the brain
perfusion status in diabetic HIP rats relative to controls. The retrieval of
fluorescent microspheres was lower in brain capillaries (but not parenchymal
tissue) of HIP rats compared to controls (Fig. 2.2g), suggesting brain
hypoperfusion in HIP rats.
Immunohistochemical analysis of brain paraffin sections (corpus callosum,
lateral ventricle area, thalamus, and hypothalamus) from diabetic rats showed
parenchymal rarefaction. HIP rat brains had a loss of MBP immunoreactivity
compared to brains from control animals (Fig. 2.3a). LFB stain of the white
matter (Fig. 2.3b) showed the same degree of myelin loss in the brains of
diabetic rats compared to controls. Vacuoles were found through the entire
white matter in HIP rats in contrast to controls.
2.3.c. Cerebral microhemorrhages and perivascular astrocyte
recruitment in HIP rats
Histologic analysis of brain tissues from HIP rats showed
microhemorrhages (Fig. 2.4a). Serial staining of the periventricular region with
the amylin antibody showed amylin deposits in microvessels and perivascular
areas (Fig. 2.4b). Vascular amylin deposition coincided with white matter
vacuolation. At higher magnification, the same brain area stained with H&E
showed loss of cellular details and erythrocytes around a blood vessel (Fig.
2.4c). Amylin was present within the vessel wall and was associated with
enlarged Virchow–Robin spaces (Fig. 2.4b, d). In contrast, tissue sections from
similar levels of the brain from a WT animal had no vascular or tissue
abnormalities (Fig. 2.4a-d). Staining for GFAP revealed robust recruitment of
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astrocytes in areas of vascular tissue damage, whereas sections taken at a
similar level of the hypothalamus from a control animal lacked obvious
abnormalities, including no astrocytosis near intact microvessels (Fig. 2.4e).
Amylin deposition was also found in association with infarction cores (Fig. 2.4f,
g) and disrupted vessel walls (Fig. 2.4h). Amylin deposition was also present
in hippocampal capillaries of HIP rats (Fig. 2.4i).
2.3.d. Cerebral microhemorrhages and perivascular astrocyte
recruitment following intravenous infusion of aggregated
amylin in AKO rats
HIP rats had elevated circulating levels of aggregated amylin (Fig. 2.1a).
To test whether circulating aggregated amylin injures the endothelium
independently of glucotoxicity, we generated rats with deleted amylin gene
(AKO rats; Fig. 2.5a, b). AKO rats were intravenously infused with aggregated
human amylin (2 µg/g body weight, every day (q.d.) for 7 days; approximately
3 orders of magnitude higher than the physiological level of amylin in HIP rats).
Western blot analysis of blood lysates from amylin-infused AKO rats, HIP rats,
and humans with type 2 diabetes showed similar distributions of amylinpositive molecular complexes (Fig. 2.5e). Infusion of aggregated amylin
provoked accumulation of amylin in the brain microvessels (Fig. 2.5f), astrocyte
recruitment in areas of vascular injury (Fig. 2.5g), and brain microhemorrhages
(Fig. 2.5h); however, the white matter in amylin-injected animals was intact as
assessed by in vivo MRI (Fig. 2.5i).
2.3.e. Vascular amylin deposition is modulated by the Amylin–
APOE interaction
To test for a possible interaction of amylin with APOE in vivo, AKO rats
(which express rat APOE, but lack amylin) were intravenously infused with
combined aggregated human amylin (2 µg/g body weight) and APOE4 (1.2
µg/g body weight), or only aggregated human amylin for 7 days (q.d.). Western
blot analysis of plasma samples from rats in the 2 groups showed greater
amylin binding to APOE4 compared to the endogenous rat APOE (Fig. 2.6a),
consistent with previous ex vivo data demonstrating that APOE4 modulates
amylin aggregation (169). To further test the interaction of amylin with plasma
APOE, plasma samples from HIP rats were enriched in APOE by
immunoprecipitation and were analyzed by Western blot with an anti-amylin
antibody. Fig. 2.6b depicts amylin that formed molecular complexes with
plasma APOE in HIP rats. Not surprisingly, amylin bound to other plasma
apolipoproteins, as indicated by the immunoreactivity signal of amylin in APOAI enriched by immunoprecipitation.
Because amylin appears to bind to APOE4 in vivo, we hypothesized that
infusion of APOE4 would exacerbate systemic amylin dyshomeostasis and
cerebral vascular injury in HIP rats. To test this hypothesis, HIP rats were
intravenously infused with APOE4 (1.2 µg/ g body weight, q.d., for 7 days). The
infusion of APOE4 enhanced amylin accumulation in the brains of HIP rats (Fig.
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2.6c). Fig. 2.6c depicts leakage of amylin from a brain microvessel of a HIP rat
that was infused with APOE4. No obvious extravasation of APOE4 was present
in the APOE4-infused HIP rats.
2.3.f. Shared feature of amylin vasculopathy in brains of HIP rats,
human amylin–infused AKO rats, and humans with dementia
and type 2 diabetes
Immunohistochemical analysis with an amylin antibody of brain tissues from
patients with type 2 diabetes and dementia showed vascular changes
associated with amylin deposition. Fig. 2.7a, b display sections from the brain
of a 93-year-old man (APOE 4/4 carrier with type 2 diabetes and CERAD
definite Alzheimer disease (AD), Braak stage V, and CAA severity 2). The
vascular histopathology includes amylin deposits in the smooth muscle layer of
arterioles and distortion of the amylin-positive vascular wall contours in
capillaries. Fig. 2.7c shows a brain section from a 92-year-old woman with type
2 diabetes and unknown APOE genotype (CERAD definite AD, Braak stage V,
and CAA severity 3). Amylin deposition was found in association with disruption
of the vessel wall. Fig. 2.7d is from the brain of another man (91 years old,
APOE 3,4 carrier, CERAD definite AD, Braak stage V, but no CAA). Amylin
immunoreactivity signal was detected in an area corresponding to a chronic
infarct. In the brain that is displayed in Fig. 2.7a, amylin is co-localized with
perivascular reactive astrocyte recruitment in disrupted blood vessel walls (Fig.
2.7e). Reactive astrocytosis was lower around blood vessels of aged control
individuals, with the caveat of the limited sample size (Fig. 2.7f). These
pathologic changes were not present in the brain blood vessels of healthy aged
individuals.
Fig. 2.7g provides a representative section from the 3 brains investigated
in this study. Immunoconfocal microscopy analysis of amylin and collagen IV,
a component of the basement membrane structure of the blood vessels, in the
brain tissue from the 91-year-old patient described above showed amylin
deposition in an arteriole and a presumed capillary profile (Fig. 2.7g). Brain
microvessels of HIP rats and AKO rats that were intravenously infused with
aggregated human amylin had similar amylin deposits as in dementia patients
who also had type 2 diabetes (Fig. 2.7h). In contrast, brain sections from a WT
rat showed no amylin staining in brain blood vessels (Fig. 2.7j).
2.3.g. Vascular amylin deposition injures endothelial cells and
degrades tight junction components
To assess the impact of aggregated amylin on the endothelium, cerebral
capillaries were isolated from HIP and WT rat brains and stained for amylin and
caveolin-1, a protein that is abundant in endothelial cells. Areas of amylin
deposition (green) showed weak immunoreactive caveolin signal, suggesting
the loss of endothelial cells (Fig. 2.8a). Consistent with immunoconfocal data,
Western blot analysis demonstrated depletion of caveolin and collagen in brain
capillary lysates from HIP rats compared to WT littermates (Fig. 2.8b). There
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was similar depletion of collagen and caveolin-1 in human amylin-infused AKO
rats (Fig. 2.8b). The transcript levels for caveolin-1 and collagen IV were
unchanged (Fig. 2.8c), suggesting that the loss of capillary stability was
associated with degradation of basement membrane structure and
endothelium.
A flow cytometry analysis of cultured brain microvascular endothelial cells
from rats was performed to test the viability of endothelial cells after exposure
to aggregated human amylin. The interaction of aggregated human amylin with
endothelial cells resulted in a significant increase of both early apoptotic
(AnV+/PI-) and end-stage apoptotic (AnV+/PI+) populations, and a reduction of
the live cell population (AnV-/PI-; Fig. 2.8d).
The tight junction components, claudin-5, occludin, and ZO-1 adapter
proteins were degraded in cerebral capillaries from HIP rats (Fig. 2.8e). There
was some reduction in tight junction components in amylin-infused AKO rats
(Fig. 2.8e). Thus, microhemorrhages and amylin vasculopathy in HIP rat brains
were associated with endothelial damage.
2.4. Discussion
Our data suggest that the amyloidogenicity of the human amylin peptide,
amylin hypersecretion, and plasma APOE are important mediators of amylin
deposition in the cerebral microvasculature. Vascular amylin deposition was
associated with endothelial cell damage and degradation of tight junctions,
which could explain the associated microhemorrhages and recruitment of
perivascular astrocytes that occurred in HIP rats and in AKO rats infused with
aggregated human amylin. Accumulated injury to cerebral small vessels can
contribute to hypoperfusion, leading to injury of brain parenchyma, loss of brain
volume, and neurologic deficits (as seen in HIP rats; see proposed mechanism
in Fig. 2.8f). Our findings are consistent with previous reports that implicated
amylin dyshomeostasis as a contributor to the development of type 2 diabetes
(37, 93, 95, 100, 119, 172) and cardiovascular disease (96, 98, 123).The most
important finding of this study is the demonstration of amylin-provoked
microhemorrhages in HIP rats and AKO rats infused with aggregated human
amylin. This provides direct evidence that diabetes-associated amylin
dyshomeostasis provokes a microangiopathy. This is a noteworthy finding
because amylin deposits are present in the brain microvessels of patients with
type 2 diabetes and dementia. Cerebral microhemorrhages occur frequently in
patients with both ischemic and hemorrhagic stroke (187) and in individuals
with CAA (162). In contrast to CAA, brain microvessels in AKO rats infused with
aggregated human amylin showed concentric amylin deposition, indicating that
circulating aggregated amylin results in luminal amylin deposition. Thus,
amylin-mediated narrowing of brain microvessels is a likely contributor to brain
hypoperfusion and parenchymal loss, leading to impaired neurological
functioning in diabetic HIP rats. Cerebral microvascular injury that occurs in
patients with type 2 diabetes is suggested to result from non-enzymatic
glycation of proteins and sub- sequent production of toxic derivatives that
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induce endothelial cell oxidative damage (25, 173). The induction of cerebral
microhemorrhages and surrounding neuropil injury occurred in amylin-infused
AKO rats in the absence of hyperglycemia, which suggests that circulating
aggregated amylin is a pathologic substrate for endothelial dysfunction in the
setting of diabetes. Further study is required to establish a causal link between
the level of circulating amylin and the effect of the resulting micro- vascular
injury on brain parenchyma and functional outcomes in humans.
The cellular and molecular mechanisms that underlie the impact of cerebral
microvascular injury on neural circuit function are complex and incompletely
understood. This limitation stems in part from a paucity of experimental models
(188, 189). In HIP rats, neurological deficits are associated with white matter
injury caused by vascular amylin deposition. The present results indicate that
expressing human amylin in species that do not develop type 2 diabetes (ie,
mice and rats) can provide a means to better understand the complex vascular
factors affecting white matter integrity in patients with diabetes and dementia.
APOE is a plasma protein that serves as a ligand for low-density lipoprotein
receptors, participates in the transport of cholesterol and other lipids among
various cells of the body (190), and is present in amylin amyloid- containing
pancreatic tissue from humans (170, 171). The infusion of APOE4 exacerbated
amylin-mediated capillary injury and brain amylin accumulation in HIP rats. The
result suggests an interaction between amylin and plasma APOE as a potential
mechanism underlying brain amylin pathology. Because APOE4 may modulate
amylin aggregation (169), we speculate that elevated levels of plasma APOE4
could trigger the formation of toxic amylin aggregates in the blood. Additional
studies are needed to elucidate the potential role of APOE alleles in promoting
vascular amylin deposition.
Amylin plays a complex role in modulating the peripheral energy balance
(55, 164-166). We demonstrated that systemic amylin dyshomeostasis
contributes to microvascular injury in the setting of diabetes. Thus, amylin
dyshomeostasis may be a therapeutic target in diabetes- associated stroke and
dementia.
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TABLES AND FIGURES
Table 2.1: Neuropathological information, APOE genotype, age and sex of
each individual included in the study in Chapter 2. The absence/presence of
diabetes was determined during life (at longitudinal clinical visits) by patient or
caregiver self-report and the use of diabetic medications (176). The assessment
of clinical dementia and the neuropathologic features-—neuritic amyloid plaques
(Consortium to Establish a Registry for Alzheimer’s Disease; CERAD), Braak NFT
stage and cerebral amyloid angiopathy (CAA) severity- were scored as previously
described (177-181).

Sex APOE Age

Diabetes

Braak
stage

CAA
severity

AD

CERAD

1
2
3

M
M
F

4/4
3/4

93
91
92

Yes
Yes
Yes

5
5
5

2
0
3

Yes
Yes
Yes

3
3
3

4

F

3/3

91

No

2

3

No

0

5

F

3/3

83

No

2

0

No

0

6

M

3/3

80

No

1

0

No

0
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Figure 2.1. Amylin, blood glucose, and neurologic deficits in rats expressing
human amylin in the pancreatic islets (HIP rats). (a) Western blot analysis of
amylin in plasma from human amylin expressing (HIP) and wild-type (WT) male
(M) and female (F) littermates, 15 months of age. (b) Blood glucose in HIP and WT
male and female littermates. (c) Spontaneous forelimb use in male HIP rats vs.
WT littermates assessed at 15 months of age by forepaws-to-wall contact time
during vertical rearing up in the cylinder test (n = 5). (d) Pathologic hind limb
clasping in a 15-month-old male HIP rat compared to a WT littermate rat. (e)
Inclined plane test in 15-month-old male HIP rats vs. WT rat littermates (n = 5). (f)
Swim speed for HIP and WT rats in the Morris water maze test (n = 10, 15–16
months old). (g) Latency for HIP and WT rats to swim to target platform in Morris
water maze test (n = 10, 15–16 months old). (h) Latency to platform in the probe
trial. Data are mean ± SEM; P ≤ 0.05 *, P ≤ 0.01 **; two-tailed, unpaired t test (a,
c, e).
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Figure 2.2. Periventricular injury and hypoperfusion in rats expressing
human amylin in the pancreatic islets (HIP rats). (a) Three slices (1, 3, and 5
of 7 consecutive slices 1mm apart) of coronal T2-weighted magnetic resonance
(MR) images comparing the brains of a 15-month-old male HIP rat vs. a WT
littermate rat. Hyperintensity areas (arrows) in the lateral hippocampus and
temporal horns of HIP rats reflect extracellular fluid accumulation. (b, c) Volumes
of ventriclular hyperintensity and brain parenchyma in male HIP and WT littermate
rats computed from coronal T2-weighted MR images; 1 image pixel area = 0.024
mm2 (n = 7). (d) Hematoxylin and eosin (H&E) staining of the lateral ventricle area
in brains of HIP rats with considerably enlarged ventricles. Arrowhead indicates
injured ependyma. (e) Immunohistochemical analysis with an amylin antibody of
the choroid plexus in the same rat as in (d). (f) Example of intracerebral
hemorrhages (arrow) that occurred in male HIP rats, but not WT littermates (>12
months of age). (g) Cerebral perfusion in male HIP and WT rats at 15 months of
age (n = 3) assessed by the retrieval from brain capillaries and parenchyma of
intravenously infused fluorescent microspheres. Data are mean ± SEM; P ≤ 0.05
*, P ≤ 0.01 **; two-tailed, unpaired t test (b, c, g). WT rat: wild-type rat.
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Figure 2.3. White matter rarefaction in rats expressing human amylin in the
pancreatic islets (HIP rats). (a) Representative immunohistochemical analysis of
myelin basic protein (MBP) in the hypothalamus (htha) of a 15-month-old male HIP
rat vs. a wild-type (WT) littermate rat. Analysis of MBP level in HIP and WT brain
white matter areas (CC = corpus callosum; HTha = hypothalamus; LV = lateral
ventricle area; Tha = thalamus; n = 3). (b) Representative IHC analysis of myelin
level assessed by Luxol fast blue (LFB) staining in the hypothalamus of a 15month-old male HIP rat vs. a WT littermate rat. Analysis was carried out in the
same brain areas as above (n = 3). (c) Scoring criteria for demyelination in myelinbinding protein and LFB staining. Exampled images of LFB staining of HIP rat brain
tissues. Data are mean ± SEM; P ≤ 0.05 *, P ≤ 0.01 **; Mann–Whitney unpaired t
test. WT rat: wild-type rat.
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Figure 2.4. Brain microhemorrhages and perivascular astrocyte recruitment
in rats expressing human amylin in the pancreatic islets (HIP rats). (a)
Analysis of the number of brain microhemorrhages stained with Prussian blue dye
in HIP vs. wild-type (WT) rats (n = 7). Representative staining with Prussian blue
dye of a microhemorrhage in the lateral hypothalamus–ventricular area of a 15month-old HIP rat is shown. The same brain area from a WT rat is the control. (b)
Representative image of serial staining with an amylin antibody in the same brain
region as in (a) shows amylin deposits in microvessels (arrows) and perivascular
area (inset; brown deposits) in HIP rats but not WT rats. White matter vacuolation
(arrowheads) was found in HIP rat brains. (c) Images with a higher magnification
(original magnification, 40x and 100x, respectively) of the same brain area stained
with hematoxylin and eosin (H&E). (d) Representative immunohistochemical (IHC)
analysis of amylin in a small arteriole (HIP vs WT rats). (e) Representative IHC
analysis of activated astrocytes in areas of vascular injury in the brain of a HIP rat
assessed by staining for glial fibrillary acidic protein (GFAP; brown). Images are
from hypothalamus. The same area from a WT rat brain is the control. (f–h) IHC
analysis of amylin in areas of microvascular injury in HIP rat brains. (i)
Representative IHC analysis of vascular amylin deposition in the hippocampus of
a HIP rat. Data are mean ± SEM; P ≤ 0.05 *; two-tailed, unpaired t test. WT rat:
wild-type rat.
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Figure 2.5. Infusion of aggregated amylin in amylin knockout (AKO) rats. (a)
Amylin gene deletion with CRISPR/Cas9. The 2 cut guide sites are shown below
in uppercase. Pre-proamylin nucleotide sequence is shown in green. (b) Gel
electrophoresis showing a 1.2kb sequence from the wild-type (WT) rat amylin DNA
and a 430bp sequence remaining after deletion of amylin gene. (c) Gel
electrophoresis showing a 650bp sequence that includes part of the amylin gene
that was deleted in transgenic animals. (d) Western blot analysis of pancreatic
tissues demonstrating that the protein level of amylin is reduced in the AKO rats
compared to WT littermates. (e) Cropped Western blot of amylin in blood lysates
from amylin-infused AKO rats, HIP rats, and T2D patients. The amylin band at
10kDa (the amylin dimer) required longer exposure time and is displayed
separately. (f, g) Representative images of immunohistochemical staining with
amylin (f) and co-staining for amylin (brown) and glial fibrillary acidic protein
(GFAP; green; g) in the cerebral cortex of an amylin-infused AKO rat vs. an agematched AKO rat without amylin infusion (n = 3). (h) Prussian blue dye in the brain
cortex area of an amylin-infused AKO rat vs. an age-matched AKO rat without
amylin infusion. Analysis of the number of brain microhemorrhages in amylininfused (inf.) AKO and control AKO rats (n = 6). (i) Three slices of coronal T2weighted magnetic resonance images comparing the brain in an AKO rat before
and after infusion with aggregated human amylin (2 µg/g body weight, every day,
7 days; n = 3). Data are mean ± SEM; two-tailed, unpaired t test. HET:
heterozygous; KO: knockout; AKO: amylin knock-out.
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Figure 2.6. Amylin interaction with plasma apolipoproteins in vivo. (a)
Cropped Western blot of amylin in plasma from amylin knockout rats infused with
amylin (AMY) alone or in combination with apolipoprotein E4 (APOE4; n = 3). (b)
Western blot analysis with an anti-amylin antibody of HIP rat plasma samples that
were enriched in APOE or APOA-1 by immunoblot (Ib) and immunoprecipitation
(Ip) (n = 3). (c) Representative immunofluorescence images of amylin–APOE4
vascular deposition in brain microvessels of HIP rats injected with human APOE4.
Analysis of amylin fluorescence intensity in the brain blood vessels of WT, HIP,
and APOE4-infused HIP rats (graph; n = 3) is shown. (d) The same as in (c) for
brain parenchyma. The bar graph shows analysis of amylin fluorescence intensity
in brain parenchyma of WT, HIP, and APOE4-infused HIP rats (n = 3). Data are
mean ± SEM; P ≤ 0.05 *; two-tailed, unpaired t test. HIP rat: human amylin
expressing rat; WT rat: wild-type rat.
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Figure 2.7. Cerebral amylin vasculopathy in patients with dementia and type
2 diabetes (T2D-De), rats expressing human amylin in the pancreatic islets
(HIP rats), and amylin-infused amylin knockout (AKO) rats. (a–d)
Representative immunohistochemical (IHC) analysis of amylin deposition (brown)
in the brain blood vessels of T2D-De patients (n = 3 patients). (e) Representative
IHC showing co-staining of glial fibrillary acidic protein (GFAP; green) and amylin
(brown) in areas of cerebral vascular injury on brain sections from the same T2DDe patients as in (a–d). (f) Representative IHC analysis with amylin and GFAP
antibodies on brain sections from healthy aged individuals (control; n = 3). (g)
Representative immunofluorescence images of amylin deposition (green) on the
luminal side of the vessel basement membrane stained with collagen IV (red) in
the brain microvessels of T2D-De patients (n = 3). Arrow indicates arteriole.
Arrowhead indicates presumed capillary profile. (h–j) Representative
immunofluorescence images of amylin deposition (green) on the luminal side of
vessel basement membrane stained with collagen IV (red) in the brain
microvessels of HIP rats (h; n = 3), amylin-infused (inf.) AKO rats (i; n = 3), and
age-matched wild-type (WT) rats (j; n = 3). WT rat: wild-type rat.
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Figure 2.8. Vascular amylin deposition injures endothelial cells and degrades
tight junction components. (a) Representative immunofluorescence images of
isolated brain capillaries from HIP and wild-type (WT) littermate rats (15 months
old) showing endothelial cells (caveolin-1, red) and amylin deposition (green; n =
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3 rats). (b) Cropped Western blot of caveolin-1 (Cav1) and collagen IV (Col IV) in
capillary lysates from HIP and WT rats (n = 5-6; left panel), and amylin-infused
(amy. inf.) amylin knockout (AKO) and control AKO (no amylin) rats (n = 3; right
panel). Corresponding densitometry analyses of caveolin-1 and collagen IV levels
are displayed in the lower panel. (c) Quantitative real-time polymerase chain
reaction of caveolin-1 and collagen IV mRNA in isolated capillaries from HIP and
WT rats (caveolin-1, n = 4; collagen IV, n = 3). (d) Flow cytometry analysis of rat
brain microvascular endothelial cell apoptosis when incubated with 50 µM human
(h) amylin (n = 3). Apoptotic cells are detected with annexin V (AnV) and dead
cells are detected with propidium iodide (PI). Live cells are AnV--/PI--, early
apoptotic cells are AnV+/PI--, end-stage apoptotic cells are AnV+/PI+, and necrotic
cells are AnV--/PI+. (e) Cropped Western blot of endothelial cell tight junction
proteins (ZO-1, occludin, and claudin-5) in capillary lysates from HIP and WT brain
(n = 5; left panel), and amylin-infused AKO and control AKO rats (n = 3; right
panel). Corresponding densitometry analyses of tight junction protein levels are
displayed in the lower panel. (f) Proposed mechanism: aggregated amylin causes
endothelial dysfunction and microvascular injury and is modulated by amylin
transport in the brain via plasma apolipoprotein E4 (APOE4). Data are mean ±
SEM; P ≤ 0.05 *; P ≤ 0.01 **, P ≤ 0.001 ***; two-tailed, unpaired t test. HIP rat:
human amylin expressing rat; WT rat: wild-type rat; AKO rat: amylin knock-out rat.
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CHAPTER 3. PANCREATIC AMYLIN CONTRIBUTES TO THE
MODULATION OF BRAIN MICROVASCULAR AND ALZHEIMER
PATHOLOGIES IN PSEN1 AND APP MUTATION CARRIERS
3.1. Introduction
Alzheimer disease (AD) affects cognition and behavior and is characterized
by β-amyloid (Aβ) plaque and tau tangle pathology in the cerebral cortex (14).
These prototypical AD pathologies commonly co-occur with vascular
abnormalities (144, 191, 192). It is suggested that there is an interplay between
these disease processes both in sporadic and familial (genetically predisposed)
forms of AD (144, 191). Accumulating evidence from several research teams
(2-7, 99, 129, 193), including our reports (2, 5, 99), indicates that the blood (5,
193) and brains (2-7, 99, 129) of individuals with sporadic AD (sAD) have
elevated levels of amylin, an amyloidogenic hormone secreted by the pancreas
(53). In the brain, amylin forms homogenous plaques (5, 129), the protein core
of some amylin-Aβ deposits (5, 129), space-filling lesions in neurons (99, 129)
and pericytes (4), and amyloid deposits in the blood vessels (2, 5, 6). No amylin
mRNA was detected in human brains (5), indicating the peripheral source of
amylin that is deposited in the brain. By considering the innate difference
between human amylin (amyloid-forming) and rodent amylin (nonamyloidogenic) (100), we also showed that pancreatic overexpression (3-fold)
of human amylin in non-AD rats provokes cerebral microhemorrhages
associated with axonal degeneration and neurologic deficits (2). The
relationship between elevated blood levels of amylin and AD pathology
remains, however, unknown.
Here, we investigated how amylin affects the brains of PSEN1 and APP
mutation carriers (familial AD; fAD), as these mutations have known
biochemical effects on AD pathology. To assess mechanistically the functional
consequences of amylin pathology seen in human brains, we generated
transgenic AD and non-AD rat models in which the consequences of elevated
blood levels of human amylin can be directly addressed in terms of AD
pathology and neurological deficits. To further test the mechanism, we
intravenously injected human amylin in AD rats that express nonamyloidogenic rat amylin. We also generated AD rats with the amylin gene
deleted to test the effects of the suppression of amylin secretion on brain
function. To further test the hypothesis that amylin dyshomeostasis accelerates
the development of AD, we pharmacologically lowered amylin dyshomeostasis
in aged ADHIP rats.
3.2. Materials and methods
3.2.a. Human samples
The protocol concerning the use of biopsy from patients was approved in
agreement with Institutional Review Board approval and informed consent was
obtained prospectively. Human brain tissues were used in this study.
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Postmortem frozen brain tissues from patients with fAD and age-matched
cognitively unaffected (CU) individuals (temporal cortex) were provided by
Queen Square Brain Bank for Neurological Disorders, UCL Queen Square
Institute of Neurology, United Kingdom. Brain tissues from fAD patients were
provided by King’s College London, United Kingdom. Brain tissues from
patients with sporadic AD (sAD) and age-matched CU individuals (Brodmann
areas 9 and 21/22) were provided by the Alzheimer’s Disease Center at the
University of Kentucky. Brain samples from CU individuals were used as
controls. Frozen brain tissues from fAD patients and controls were used for
biochemical analyses. For immunohistochemistry, formalin-fixed, paraffinembedded brain tissues from sAD patients, fAD patients, and age-matched
controls were used. Details on patient information and sample size can be
found in Table S3.1.
3.2.b. Experimental animals
This investigation conforms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publication No.
85-23, revised 2011) and was approved by the Institutional Animal Care and
Use Committees at University of Kentucky. Alzheimer disease (AD) model rats
(TgF344-19, provided by RRRC) are Fischer rats that express human Aβ (A4)
precursor protein (hAPP) gene with the Swedish mutation (K595N/M596L), and
presenilin 1 (PSEN1) gene with a deletion of exon 9, driven by mouse prion
promoter (Prp) (194). HIP rats (provided by Charles River Laboratory) are
Sprague-Dawley rats that overexpress (3-fold) human amylin in the pancreatic
β-cells (95). The AD rats (n = 10) were crossbred with HIP rats (n = 10) to
generate rats of four genotypes: wild-type, HIP, AD, and rats that are triple
transgenic for human amylin, APP, and PSEN1 (ADHIP rats). A total of n = 135
male and female rats were generated to obtain the predicted number of rats for
differentiating between the effects of amylin pathology and Aβ pathology on the
behavior deficits in ADHIP rats. Male ADHIP (n = 10), AD (n = 10), HIP (n =
10), and WT rats (n = 10) were used in behavior testing and physiological
analyses. Amylin knock-out in AD model rat (AD-AKO) was generated by first
crossbreeding AD rats (n = 4) with AKO (n = 3) rats. The generation of AKO rat
model was described previously (2). A total n = 162 male and female rats were
generated to obtain the predicted number of rats to uncover the effects of
amylin gene deletion on the behavior deficits in AD-AKO rats. Male AD and ADAKO littermates (n = 8-9/group) were used in behavior testing and physiological
analyses. Blood glucose and weights were measured monthly in all rats. Animal
physical health was followed and documented. Rats were housed in a
temperature-controlled room under a 12-hour light/dark cycle with free access
to food and water. All rats were fed a normal chow diet. In this study, we used
male rats because amylin dyshomeostasis develops earlier in males (~12
months) than in females (> 18 months) (2).
3.2.c. Genetic analysis
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The specific association of genetic variants in IAPP identified by the
International Genomics of Alzheimer’s Project (IGAP) consortium was
analyzed. These results correspond to the meta-analysis of genotyped and
imputed data (7,055,881 SNPs, 1000G phase 1 alpha imputation, Build 37,
Assembly Hg19) of 17,008 AD cases and 37,154 controls. To assess rare
genetic variants in IAPP (ENST00000240652) in AD, the exome sequencing
data from a UK cohort of 331 AD cases were analyzed. The variability of the
IAPP gene in a cohort of healthy elderly samples from the Healthy Exomes
(HEX) database was also analyzed. HEX includes data corresponding to the
exome sequencing of 468 individuals categorized as cognitively healthy and
neuropathologically normal (195). Given the finding of p.Asn64fs in a healthy
sample aged >90 years, loss of function variants described in gnomAD, and
the respective available information for age was examined (Table S3.2).
3.2.d. Antibodies and reagents
The following primary antibodies were used: Amylin (1:200, T-4157,
Bachem-Peninsula Laboratories), human Aβ (1:300, clone 6E10, Biolegend),
phosphorylated tau (1:400, clone AT8, MN1020, Pierce). The following
secondary antibodies were used: Biotinylated anti-rabbit IgG (1:300, BA-1100,
Vector), AP-conjugated anti-mouse IgG (1:100, A3562, Sigma), Alexa Fluor
568 anti-rabbit IgG plus (A11036) and Alexa Fluor 647 anti-mouse IgG plus
(A21236), Alexa Fluor 488 anti-mouse IgG (A11029), Alexa Fluor 488 antirabbit IgG (A11034), and Alexa Fluor 568 anti-mouse IgG (A11031), and antirabbit IgG (1:2,000, 32460) from Thermo Fisher. The following reagents were
used: DAB chromogen substrate (ab64238, Abcam), AEC chromogen
substrate (SK-4200, Vector), StayGreen/AP chromogen substrate (ab156428,
Abcam), citrate buffer (S1699, Dako), Thioflavin S (1326-12-1, Sigma), Sudan
black (4197-25-5, Sigma), luxol fast blue dye (AC212170250, Acros Organics),
potassium ferrocyanide (AC211095000, Acros Organics), Congo Red (C58025, Fisher), and lyophilized amidated human amylin peptide (AS-60254,
Anaspec). BCA (23225) and Micro-BCA (23235) protein assays are from
Thermo Fisher Scientific. All other reagents are from Thermo Fisher Scientific
unless specify.
3.2.e. Bio-fluid collection from animals
CSF was collected from isoflurane-anesthetized rats every two months by
inserting needles through the cisterna magna without any skin incision (protocol
was described in (196)). CSF was obtained by syringe aspiration. The volume
extracted did not exceed 120 µL per each collection. Blood was collected
through the tail vein by syringe aspiration. EDTA was added to blood samples
to prevent coagulation. The collection volume did not exceed 500 µL per each
collection. Red blood cells and plasma were separated by centrifugation at
1,000 xg for 10 minutes at 4oC. Samples were stored at -80oC.
3.2.f. Amylin aggregation and injection
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Lyophilized amidated human amylin peptide was dissolved in PBS pH 7.4
to the concentration of 50 µM. The mixture was incubated in 370C for 72 hours
with occasional shaking to allow amylin to form aggregates. Every 3 days
aggregated human amylin solution was injected into 7 months old AD rat via
tail vein (60 µg/kg). The age-matched AD control group received the same
volume of PBS per injection without aggregated human amylin. The animals
received injections for 60 days. Bio-fluids from each animal were collected
before- and post-injection.
3.2.g. Pharmacological treatment on animals
To increase epoxyeicosatrienoic acids (EETs) levels, the animals were
treated with TPPU (1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)
urea, N-[1-(1-Oxopropyl)-4-piperidinyl]-N′-[4-(trifluoromethoxy)phenyl]-urea), a
soluble epoxide hydrolase inhibitor (sEHi) (HY-101294, MedChem Express).
12 months (n = 5; early-stage) and 16 months (n = 6; late-stage) old ADHIP
rats were subjected to treatment with sEHi. Age-matched ADHIP rats that
received vehicle treatments (n = 5 for early-stage; n = 6 for late-stage) were
used as controls. TPPU was dissolved in PEG-400 at 60oC, overnight, and was
diluted in drinking water or PBS for injection (122). For treatment at early stage
(ES), the drug was administered through drinking water (3mg/L, daily) and
intravenous injection (20 µg/kg, once a week) to ensure equal intake for each
animal. For treatment at late stage, the drug was administered through
intravenous injection (20 µg/kg, daily, 1 month) and then through drinking water
(3 mg/L, daily, 1 month). The amount of water intake was measured daily.
3.2.h. Behavior testing
Cognitive function
Novel Object Recognition (NOR): The NOR test was used to test for shortterm recognition, as previously described (8).
Morris Water Maze: Spatial learning and long-term memory retention were
tested in a 1.5 m diameter Morris Water Maze, as previously described (2).
Animals were given 4 learning trials per day for four consecutive days using
random starting locations. Animals were allowed to stand on the platform for
30 seconds after the first trial and 15 seconds after each additional trial. If the
animals failed to locate the platform, they were picked up and put on the
platform for 15 seconds. To assess reference memory, a probe trial was given
24 hours after the fourth acquisition day. Trials were recorded by EthoVision
XT software (Noldus, VA). In the 8-month old rat group, 2 AD rats and 3 ADHIP
rats were not performing (floating/ non-learning). In the 12-month old rat group,
1 HIP rat was not performing. In the 16-month old rat group, 4 HIP rats and 1
AD rat were not performing. Non-performing rats were excluded from the
analysis. After locating the platform, AD-AKO rats had difficulty to climb on the
platform due to heavy body weights; thus, the difficulty discourages animals
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from finding escape in later trials. The result from the water maze test excluded
from the behavior analysis for AD-AKO rats.
Motor function
Forelimb use test/ Cylinder test, inclined plane, hind limb clasping test:
Experimental protocols were described previously (2). The rat’s forelimb
deficits were evaluated by forelimb-to-wall contact time in the cylinder test. The
rat’s balancing ability was determined by recording the angle at which the
animal started to slip on a rising inclined plane. Abnormalities in the rat’s hind
limbs were assessed by scoring the severity of hind limb clasping (197).
Because of the impact of the amylin gene deletion on the body weight (see
data), the result from the inclined plane test was not taken into the behavior
analysis for AD-AKO rats.
Rotarod assessment: Motor coordination and balance were tested by the
Rotarod (Rotamex 5, Columbus Instrument, OH) test (8). Animals were
acclimatized to the static rod 2 days before testing. On the testing day, the
speed of the rotarod was increased from 0 rpm to 40 rpm within 2 minutes.
Each rat was tested on the Rotarod for a total of 4 trials per day over 5
consecutive days. For each training day, the smallest value of latency-to-fall for
each rat was discarded. The remaining read-outs were averaged, and a group
average was calculated for each genotype. In the 8-month old AD rat group,
two rats were not performing. In the 8-month old ADHIP rat group, one rat was
not performing. In the 12-month old AD rat group, 3 rats were not performing
on day 1, 5 rats were not performing on day 2, and 7 rats were not performing
on days 3-5. In the 16-month old AD rat group, 4 rats were not performing in all
days. In the 12-month old WT rat group, 4 rats were not performing. In the 16month old HIP rat group, 4 rats were not performing. Non-performing rats were
excluded from the analysis. Because AD-AKO rats were too large to fit on the
rotarod, AD-AKO rats could not perform on the rotarod; hence, this assessment
was excluded from the behavior analysis for AD-AKO rats.
Composite z-score analysis for behavior tests
The composite z-score analysis method was previously described (198).
For each behavior test, mean and standard deviation were calculated from
individual variables collected from longitudinal assessments from animals
across the experimental groups. Z-score (neurological score) for each animal
in each behavior test was calculated using the following equation:
𝑧 − 𝑠𝑐𝑜𝑟𝑒 =

𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒 − 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒 𝑚𝑒𝑎𝑛
𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛

The composite score for each animal was calculated by averaging z-scores
from each test.
3.2.i. Magnetic resonance imaging (MRI)
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MRI scans were performed on ADHIP and AD littermates using a horizontal
7T nuclear MRI scanner (ClinScan, Brucker BioSpin MRI, Ettlingen, Germany)
as described in ref. 7. Coronal T2-weighted images were obtained using
generic parameters: field of view (FOV) 40 mm, repetition time (TR) 3000 ms,
echo time (TE) 24 ms, slice thickness 1 mm, inter-slice gap 1 mm, 7 slices.
Ventricular hyperintensities volume was calculated as described in ref. (2).
3.2.j. Histology and demyelination scoring
Microhemorrhages in rat brains were identified with Prussian blue dye and
analyzed as described in ref. (2). Congo red staining was performed on the
human brains as described in ref. 5. Myelination in rat brains was analyzed by
staining with luxol fast blue (LFB) dye (2). Scoring was performed by observers
that were blinded to the experimental groups as described in ref. (2).
3.2.k. Immunohistochemistry
We used formalin-fixed, paraffin-embedded brain, and pancreas tissues
from humans, wild-type, HIP, ADHIP, AD, and AD-AKO rats. Tissues were
processed as described in (2, 5, 99). After tissue rehydration, the endogenous
peroxidase was quenched in 3% H2O2 in methanol for 30 minutes. For amylin
and Aβ antigen retrieval, sections were treated with 100% formic acid for 5
minutes at room temperature (R.T.), followed by 0.5% pepsin digestion in 5mM
HCl for 20 minutes at 37oC. To retrieve other antigens, tissue sections were
heated in citrate buffer for 30 minutes. Non-specific antibody binding was
blocked by 15% horse serum for 1 hour at R.T. Primary antibodies against
amylin or human Aβ was incubated on slides overnight at 4oC. Sections were
then washed and incubated with secondary antibodies. Signal was developed
with AEC peroxidase substrate. For co-staining with two antibodies, after the
signal was developed for the first antibody, sections were then rinsed in water.
Non-specific antibody binding was blocked with 10% normal goat serum, and
the sections were incubated with the second primary antibody overnight at 4oC.
Sections were then washed and incubated with an AP-conjugated secondary
antibody and developed with StayGreen/AP chromogen substrate. Sections
were mounted with aqueous mounting medium. Amylin antibody specificity was
established in our previous studies (2, 5, 99).
Image analysis: Images were obtained using Nikon Eclipse 55i upright
microscope and NIS-Element Software. The immunoreactivity signal for each
antibody was analyzed by ImageJ. Signal pixels were selected to establish the
RGB profile of the color of interest. The threshold for each color signal was
adjusted to reduce background noise. The established RGB profile and
threshold were applied to a macro script command, using Color Deconvolution
plugin in ImageJ. The percentage of area positive for the immunoreactivity
signal was calculated using ImageJ. Clearly defined plaques that are larger
than 20 µm in AD and ADHIP rat brains were counted. The number of plaque
counts were normalized to the total imaging area.
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3.2.l. Immunofluorescence staining
Immunofluorescence staining for brain tissue sections was modified from
the previously described protocol (2, 99). The antigen retrieval method for
amylin and Aβ is modified. The antigen retrieval for amylin and Aβ was
described in the immunohistochemistry session above. For Thioflavin S
staining, after secondary antibody incubation, brain slides were incubated in
0.5% Thioflavin S for 15 minutes at R.T. Slides were then incubated for 3
minutes in 70% ethanol, 3 minutes in 0.2% Sudan black and 3 minutes in 70%
ethanol, before washing and mounting.
3.2.m. Isolation of rat brain capillaries
Rat brain capillaries were isolated following the protocol described
previously (199). Freshly isolated brain capillary was snap frozen, crushed and
homogenized in homogenate buffer (150 mM NaCl, 50 mM Tris-HCl, 50 mM
NaF, 2% Triton X-100, 0.1% SDS, 1% (v/v) protease and phosphatase
inhibitors, pH 7.5). Homogenates were centrifuged at 17,000 xg for 30 minutes
at 4oC. The supernatant was separated from pellet after centrifugation and was
then used for all experiments.
3.2.n. Protein extraction
Frozen human brain tissues were homogenized in homogenate buffer (150
mM NaCl, 50 mM Tris-HCl, 50 mM NaF, 2% Triton X-100, 0.1% SDS, 1% (v/v)
protease and phosphatase inhibitors, pH 7.5). Homogenates were centrifuged
at 17,000 xg for 30 minutes at 4oC. The supernatant was separated from pellet
after centrifugation and was then used for all experiments. For rat brain tissue,
half hemisphere was used for histological analyses, and the other half was
used for brain capillary isolation and other protein extractions. Rat brain tissues
were subjected to serial extraction methods using Triton and Guanidine HCl
(GndHCl). Frozen brain samples were homogenized with 1% Triton buffer (25
times tissue volume) containing 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100 (v/v), 1% (v/v) protease and phosphatase inhibitors,
pH 7.5. The homogenates were left on ice for 15 minutes. The homogenates
were centrifuged at 15,000 rpm for 15 minutes at 4oC. The supernatant (Tritonsoluble fraction) was separated from the pellet. 5 M GndHCl (with 50 mM Tris,
pH 8.0) solution was added to the pellet (10 times the pellet volume).
Homogenates were rocked for 3-4 hours at R.T. The samples were stored at 80oC until analysis. Before analysis, the GndHCl samples were diluted at 1:10
ratio with lysate buffer (1% NP-40 (v/v), 150 mM NaCl, 10 mM Tris, 2 mM
EGTA, 50 mM NaF). The samples were centrifuged at 16,000 xg for 20 minutes
at 4oC. The supernatant (GndHCl-soluble fraction) was separated from the
pellet. BCA protein estimation was performed for Triton-soluble fractions.
MicroBCA protein estimation was performed for diluted GndHCl-soluble
fraction.
3.2.o. Enzyme-linked immune absorbance assay (ELISA)
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Levels of amylin in human brain samples were measured using sandwich
amylin ELISA from Millipore (EZHA-52K). Levels of amylin in brain homogenate
and CSF samples from rats were measured using amylin sandwich ELISA from
RayBiotech (EIA-AMY). Total Aβ levels in rat CSF were measured using high
sensitivity electrochemiluminescence ELISA (MSD 6E10, K15200G-2, Meso
Scale Discovery). Aβ42 and Aβ40 levels in rat brains were measured using
Aβ42 and Aβ40 ELISA (KHB3442, KHB3482, Invitrogen). ELISAs were
performed according to the manufacturer’s protocol. Levels of measured
proteins in tissue homogenates were normalized to the total protein input.
3.2.p. Statistical analysis
The number of samples or animals analyzed in each experiment, the
statistical analysis performed, as well as the P values for all results are reported
in the figures and figure legends. The reported ‘‘n’’ represents the number of
animals. Gaussian distribution of the data was tested with D'Agostino-Pearson
and Kolmogorov-Smirnov test. Parametric comparison between two groups
was performed using two-tailed t-tests. Relationships between two variables
were analyzed by correlation analysis. Z-scores and data from the Morris Water
Maze were analyzed by ANOVA, followed by post-hoc tests. Analyses were
performed using GraphPad Prism 8.0. Data are presented as means ± SEM,
individuals, or as box and whisker plots. The difference between groups was
considered significant when P ≤ 0.05.
3.3. Results
3.3.a. Brains of fAD mutation carriers contain amylin deposits in
microvasculature and plaques.
Amylin is known to form pancreatic amyloid in patients with type 2 diabetes
(Fig. S3.1a) and also interacts with AD pathology in individuals with sporadic
AD (sAD) (2-7, 99, 129). To test the potential relationship between pancreatic
amylin, the brain and fAD, we analyzed brain tissues from human PSEN1 and
APP mutation carriers for amylin deposition and interaction with areas of ADrelated histopathology (Aβ and tau deposits). Details on patient information are
given in Table S3.1. Temporal cortex homogenates from fAD patients had
higher amylin concentrations compared to those from cognitively unaffected
(CU) individuals (Fig. 3.1a). The average amylin levels were higher in brain
homogenates from PSEN1 mutation carriers than in APP mutation carriers and
in CU individuals (Fig. S3.1b). Immunohistological analysis uncovered amylin
and mixed amylin-Aβ plaques in fAD brains (Figs. 3.1b-l) (see also Methods;
Image analysis). Amylin was detected in about 1/3rd of the total plaques within
the grey matter of fAD brains (Figs. 3.1b, d). Brains from the CU group had
sporadic amylin and Aβ deposits (Fig. 3.1c). Within the CU group, cerebral
plaques showed a higher immunoreactivity signal compared to that of Aβ (Fig.
3.1e), which was anticipated based on previous reports (5, 6, 99, 100, 129) that
amylin accumulates in both cognitively unaffected and sAD brains.
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In fAD brains, amylin immunoreactivity was detected in neuronal soma
(Figs. 3.1f and 3.1g; arrowheads; 26/27 patients (Table S3.1)) and neuritic
plaques (Figs. 3.1h-l, 16/27 patients (Table S3.1)). In some amylin-Aβ neuritic
plaques, immunostaining showed the presence of amylin in small
proteinaceous fragments (Figs. 3.1f and 3.1g; arrows). Confocal microscopic
analysis of areas containing amylin-positive neurons revealed no overlapping
between the immunoreactivity signals for amylin and phosphorylated tau (ptau) (Fig. S3.1c) suggesting distinct amylin and tau pathologies. Some plaques
stained positive for amylin adjacent to Aβ deposition (Figs. 3.1h and 3.1i), and
some had layered amylin-Aβ compositions with amylin-positive cores (Figs.
3.1j-l). CU brains showed sparse amylin and Aβ immunoreactivity signals (Fig.
3.1m). Confocal microscopic analysis of fAD brain slices triple-stained with
Thioflavin-S and anti-amylin and anti-Aβ antibodies suggests that the amylinpositive core of amylin-Aβ plaques has biochemical characteristics of amyloid
because it is localized with Thioflavin-S signal (Fig. 3.1n) and is structurally
similar to those detected in brain slices from patients with sAD (Fig. S3.1d).
Amylin deposition was present in both grey matter (GM) and white matter
(WM) regions (Figs. 3.2a-c). Sparse amylin immunoreactivity signal was
detected also in CU brains (Fig. 3.2b). In fAD, while Aβ was predominantly
deposited in GM areas, the area of amylin deposition is higher than that of Aβ
in the WM (Fig. 3.2c).
In humans, AD pathology co-occurs with vascular abnormalities (15) and
BBB injury (192). Co-staining human fAD brain tissues for Aβ and amylin
showed the presence of mixed amylin-Aβ immunoreactivity signals within the
blood vessel wall and Aβ surrounding the blood vessel in GM regions (Fig.
3.2d), compared to CU brains (Fig. 3.2e). The average amylin content in
vascular mixed amylin-Aβ deposits was higher in brain tissues from PSEN1
mutation carriers than in APP mutation carriers and in CU individuals (Fig.
3.2f). Amylin formed amyloid in small arteries as inferred from serial sections
tested for amylin deposition and Congo red staining (Figs. 3.2g-j). This result
mirrors previous findings in sAD brains, where amylin deposition within blood
vessels walls appeared as part of cerebral amyloid angiopathy (CAA) (5,
6).Figures 3.2k-n show a presumed capillary positive for amylin and ThioflavinS, but negative for Aβ, indicating that capillary amylin deposition has
biochemical characteristics of amyloid. In WM regions, amylin deposition was
detected in occluded small vessels (Fig. S3.2 (arrowheads)), in perivascular
and chronic infarct areas (Fig. S3.2 (arrows)), and in the parenchyma (Fig.
S3.2 (double arrows)). Pancreatic tissue from a patient with type 2 diabetes
served as positive control for amylin deposition (Fig. S3.1a).
3.3.b. Amylin-AD
predisposition.

interaction

does

not

involve

a

genetic

A variant in the amylin gene (rs73069071) was associated with cortical Aβ
deposition in patients with AD-related cognitive impairment and temporal lobe
atrophy in a genome-wide interaction study (137). To test whether genetic
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predisposition may play a role in amylin-AD interaction, we analyzed specific
associations of the amylin gene variants with the risk for developing AD using
data from the International Genomics of Alzheimer’s Project (IGAP) (n = 17,008
AD cases and n = 13,154 controls). No significant associations were detected
for the amylin gene. To assess rare genetic variants in the amylin gene
(ENST00000240652) in AD, we analyzed exome sequencing data from a
cohort of 331 AD cases (Table S3.2). We also analyzed the variability of the
amylin gene in a cohort of cognitively healthy and neuropathologically normal
individuals (n = 468) from the Healthy Exosomes (HEX) database (Table S3.2).
Our analysis showed no genetic role of amylin in AD.
These results suggest that amylin secreted from the pancreas may
contribute to small-vessel-type pathology in white matter and grey matter
regions and modulate brain amyloid composition in fAD via mechanisms that
are not linked to a genetic predisposition.
3.3.c. Co-expression of amyloid-forming human amylin in the
pancreas and APPSwe/PS1DE9 in the brain accelerates neurological
deficits in rats (ADHIP rats).
The rat experimental models used in this study are summarized in Fig. 3.3
schematic. To test the impact of brain amylin deposition on behavior deficits
associated with AD pathology, we generated AD model rats that are prone to
amylin dyshomeostasis (ADHIP rats). The model was created by crossing nonAD rats that overexpress human amylin (3-fold) in the pancreas (HIP rats) (95)
and develop systemic amylin dyshomeostasis on a normal chow diet (2) (8, 95,
98, 123) with APP/PS1 rats that overexpress human APPSwe/PS1DE9 (194)
without amylin dyshomeostasis (AD rats) (Fig. 3.3), as rat amylin does not form
amyloid (100). HIP and wild type (WT) rats from the same litters as ADHIP and
AD rats were used to assess the effects of amylin dyshomeostasis on behavior,
in the absence of AD pathology (Fig. 3.3). Rats in all groups were tested for
motor and cognitive performance at 8 (normal behavior), 12 (development of
amylin dyshomeostasis in HIP rats) (2, 8), and 16 months of age (development
of AD pathology in AD rats) (194). At 8 months of age, ADHIP rats and AD rats
had comparable neurological scores for motor and cognitive performance (Fig.
3.4a). With aging, rats in the ADHIP group had greater deficits for both motor
(Fig. 3.4b and Figs. S3.3a-d) and cognitive (Fig. 3.4c and Figs. S3.4a-c)
function, which worsened at a higher rate than those in AD littermates (Figs.
3.4b-c). Motor and cognitive performance declined faster also in aged HIP rats
than in WT littermates (Figs. 3.4d-f and Figs. S3.3e-h and S3.4d-f). Multiple
comparison analysis between rat groups at each time point suggests that
amylin-AD pathology interaction accelerates functional decline, beginning at 12
months of age (Fig. 3.4a). The analysis also indicates that the amylin-AD
pathology interaction synergistically augments the behavioral deficits with
aging (schematic summary in Fig. 3.4g).
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3.3.d. Accelerated behavior deficits in ADHIP rats are associated
with brain microhemorrhages and white matter changes.
We reported (2, 97) that high blood levels of amyloid-forming human amylin
in HIP rats are associated with disruption of vascular endothelium associated
with brain microhemorrhages and white matter disease (2).
Immunohistochemistry analysis of brain slices from 16-month old ADHIP and
AD littermates co-stained for amylin (red) and Aβ (green) (Figs. 3.5a-b)
revealed vascular amylin deposition in both GM and WM regions, in ADHIP
rats. Amylin also paired with Aβ in blood vessels (Fig. 3.5a). AD littermates had
no significant amylin or Ab deposition in brain blood vessels (Figs. 3.5c-d).
Based on these results, we anticipated two consequences from the amylinmediated microvascular changes: brain microhemorrhages and white matter
injuries (schematic, Fig. 3.5e).
Brain microhemorrhages: In brain tissues from ADHIP, AD, HIP, and WT
rats, we analyzed: 1) the presence of brain microhemorrhages, by Prussian
blue staining; and 2) vascular recruitment of monocytes and macrophages, by
immunohistochemistry using antibodies against Cluster of Differentiation 68
(CD68) and 11b (CD11b) molecules. Aged ADHIP rats had more
microhemorrhages than AD littermates (Fig. 3.5f). Brain microhemorrhages
were also detected in HIP rat brains (Fig. 3.5g). Histological analysis of brain
tissues revealed greater accumulation of phagocytic microglia, a marker of
blood-brain barrier (BBB) damage (192), in the GM and WM of aged ADHIP vs.
AD rats and in HIP vs. WT rats (Figs. 3.5h-i).
Brain white matter changes: Next, we investigated aged ADHIP rats and
AD littermates by in vivo brain magnetic resonance imaging (MRI) followed by
analyses of brain slices for evidence of axonal degeneration by staining with
myelin basic protein antibody and luxol fast blue. In vivo structural MRI of the
brain revealed areas of high T2 signal in the lateral hippocampus and around
the temporal horns of the lateral ventricles (Fig. 3.6a) and expansion of the
ventricles (Fig. 3.6b) in aged ADHIP rats, which were not present in AD
littermates. Consistent with subcortical atrophy, ADHIP rats had lower brain
weight (Fig. 3.6c), compared to AD littermates. The results from ADHIP vs. AD
rats are in agreement with our published comparative analysis in HIP vs. WT
rats (2). Histological analysis of brain tissues revealed greater levels of axonal
degeneration in aged ADHIP vs. AD rats and in HIP vs. WT rats (Fig. 3.6d and
Fig. S3.5).
Brain microhemorrhages following intravenous injection of human
amylin in AD rats: We tested whether abnormal circulating levels of amyloidforming human amylin affect brain microvasculature in the absence of
confounding factors due to development of amylin dyshomeostasis (at ~ 12
months of age, in ADHIP rats) and AD pathology (at ~ 16 months of age, in AD
rats). We infused low amounts of oligomerized human amylin intravenously in
young AD rats (7 months of age), for 2 months (Fig. 3.6e). At the conclusion of
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the infusion regimen, rats injected with human amylin had increased amylin
concentration in brain capillary lysates (Fig. 3.6f) and developed brain
microhemorrhages (Fig. 3.6g), indicating disruption of brain microvascular
endothelium as seen in ADHIP rats (Fig. 3.5f).
3.3.e. APPSwe/PS1DE9 and
amylin-Aβ cross-seeding.

amylin

dyshomeostasis

promote

Altered composition of secreted amylin in ADHIP vs. AD rats was
associated with changed dynamics of the CSF Aβ concentration with aging
(Fig. 3.7a). The ratio Aβ42/Aβ40 protein levels were higher in brain homogenates
from ADHIP rats than in those from AD littermates (Fig. 3.7b) suggesting an
increased propensity for plaque formation in ADHIP rats. These changes were
associated with increased plasma amylin levels with aging (Fig. 3.7c) and brain
accumulation of amylin (Fig. 3.7d) in ADHIP vs. AD rats, indicating amylin
dyshomeostasis in ADHIP rats. Immunohistochemistry analysis of brain slices
from 16-month old ADHIP and AD littermates co-stained for amylin (red) and
Aβ (green) (Figs. 3.7e and 3.7f) revealed amylin deposition in both GM and
WM regions in ADHIP rats (Fig. 3.7e), mirroring findings in human AD brains
(Fig. 3.1b). The amylin WM to GM coverage ratio was elevated in ADHIP
compared to AD brains (Fig. 3.7g) and tended to increase in 16-month old
compared to 12-month old ADHIP rats (P = 0.06), consistent with progression
of amylin dyshomeostasis. A similar analysis in the HIP vs. WT rats (Figs. 3.7hm) suggests that elevated blood levels of amyloid-forming human amylin (Fig.
3.7h) are associated with altered CSF Aβ concentration (Fig. 3.7i), brain amylin
accumulation (Fig. 3.7j) and amylin pathology in WM regions (Figs. 3.7k-m).
These data indicate that amylin dyshomeostasis induced by expressing human
amylin in the pancreas of AD model rat promotes amylin interaction with brain
Aβ and changes in brain white matter (summarized in Fig. 3.7n).
Based on our reported data in HIP rats (2), amylin pathology in the WM
microvasculature in ADHIP rats (as in Figs. 3.5a and 3.7e) is an intrinsic
constructive validity of the ADHIP model rat linked to the expression of human
amylin in the pancreas. ADHIP and HIP rats differed, however, by the
composition of protein deposition in GM regions. In ADHIP rats, amylin formed
the protein core of the Aβ plaques (Fig. 3.8a and Fig. S3.6a). AD littermates
had Ab plaques in GM regions (Fig. 3.8b and Fig. S3.6a), as reported (194).
GM regions in HIP rat brains had sparse amylin deposition, without obvious Ab
immunoreactivity signal (Fig. 3.8c). Brains of WT littermates had neither amylin
nor Aβ deposition (Fig. 3.8d). Pancreatic tissues from rats in the four groups
were used as positive controls for characteristic amylin immunoreactivity
signals in each rat group (Figs. 3.8e-h).
Intriguingly, sparse amylin deposition within the protein core of Aβ plaques
was detected in brain tissues from 16-month old AD rats (Fig. 3.8b and Figs.
S6a), although amylin from rodents is non-amyloidogenic (100). There was no
hippocampal amylin plaques deposition in WT rats (Figs. S3.6a-b) suggesting
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that rat amylin does not accumulate in the brain, in non-AD rats that express
endogenous non-amyloidogenic rat amylin.
To determine cerebrovascular effects of amylin dyshomeostasis induced
before the development of AD pathology, we examined the pathology in AD
rats that were infused with low amounts of human amylin, as described above
(Fig. 3.6e). Infusion of human amylin did not significantly increase the plasma
amylin level in AD rats (Fig. S3.6c). At the end of the infusion regimen,
cognitive and motor performance were not significantly different between AD
rats that were given human amylin vs. control rats (Fig. S3.6d). Brain tissue
sections co-stained for amylin and Aβ showed amylin-Aβ plaque formation
(Fig. S3.6e, arrow) and patchy areas of amylin-positive neurons (Fig. S3.6e,
circles). These data suggest that human amylin from the periphery promotes
amylin-Aβ plaque formation in the brain and neuronal amylin accumulation,
before the development of AD pathology.
To test the source of brain amylin deposition in AD rats, we generated
APPSwe/PS1DE9 rats that lack the amylin gene (AD-AKO rats) by crossing
APPSwe/PS1DE9 rats with amylin knockout (AKO) rats (AKO rats were
generated in our previous work (2)). Deletion of amylin gene in AD rats resulted
in no amylin deposition in the brain GM parenchyma (Fig. 3.8i), blood vessels
(Fig. 3.8j), brain WM (Fig. 3.8k), or the pancreas (Fig. 3.8l), providing critical
evidence that the pancreas is the source of amylin that is deposited in the brain.
The number of mixed amylin-Aβ plaques also significantly less in AD-AKO
group (Fig. 3.8m), suggesting that the genetic suppression of amylin decreases
amylin-Aβ cross-seeding.
Overall, these results (Figs. 3.7 and 3.8a-m) suggest that: 1) amylin
dyshomeostasis disrupts the CSF-brain Ab balance; 2) there is a robust in vivo
amylin-Aβ cross-seeding promoted by overexpression of human
APPSwe/PS1DE9; 3) APPSwe/PS1DE9 rats with the pancreatic expression of
human amylin mirror amylin-Aβ cross-seeding in PSEN1 and APP mutation
carriers.
3.3.f. Suppressed amylin expression reduces behavior deficits in
APPSwe/PS1DE9 rats.
The unexpected cross-seeding between rat amylin and Aβ in brains of AD
rats suggested the hypothesis that suppression of amylin secretion affects
neurological function in AD rats. Neurological function changes with aging in
AD-AKO rats vs. AD littermates are shown in Figs. 3.8n-p. Overall, AD-AKO
rats had less severe neurological deficits with aging compared to AD rats (Fig.
3.8n), an unanticipated result indicating that amylin depletion protected against
AD effects because rat amylin is non-amyloidogenic (100). The cognitive
function, assessed from the novel object recognition, declined significantly
slower in AD-AKO rats, compared to AD (Fig. 3.8o). The novel object
recognition test, which detects short-term recognition memory impairments,
differed between AD and AD-AKO rat groups at 16-months of age (Fig. S3.7a).
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The motor function assessed from the forelimb use (Fig. S3.7b) and hind limb
clasping (Fig. S3.7c) was not significantly different between AD and AD-AKO
at 8-, 12-, and 16-months of age (Fig. 3.8p). Consistent with amylin’s function
as a satiation hormone (55), suppression of amylin expression caused the body
weights of AD-AKO rats to increase at a greater rate than those of AD
littermates (Fig. 3.8q). Because of the impact of the amylin gene deletion on
the body weight, the results from the inclined plane, rotarod, and water maze
tests were not included in the analysis.
3.3.g. The pharmacological lowering of amylin dyshomeostasis
improves brain function in Alzheimer disease model rats.
To further test the hypothesis that amylin dyshomeostasis accelerates the
development of AD, we pharmacologically lowered amylin dyshomeostasis in
aged ADHIP rats and assessed behavior, brain amylin-Ab depositions, cerebral
vascular, and white matter injuries in treated and untreated rat groups. ADHIP
rats were treated with an inhibitor of soluble epoxide hydrolase (sEH), the
enzyme that degrades endothelial cell-formed epoxyeicosatrienoic acids
(EETs). EETs was shown to protect against cardiac amylin deposition in a rat
model for amylin dyshomeostasis (122). Separate cohorts of ADHIP rats were
treated starting at different disease stages of amylin dyshomeostasis (2, 8): 12month old (early-stage (T-ES)) and 16-months old (late-stage (T-LS)). Agematched control animals in each study group received vehicle treatment (UTES and UT-LS). The schematic of treatment regimen is in Fig. 3.9a. Here, we
found that both treatments with sEH inhibitor (sEHi) slowed the neurological
deficits in ADHIP rats (Fig. 3.9b, Figs. S3.8a-n). At the end of the treatment,
amylin concentration in plasma and brain homogenates was significantly lower
in rats treated at an early stage, compared to age-matched 16M old UT rats
(Figs. 3.9c and d). ADHIP rats treated at late stage also had lower levels of
plasma amylin (P = 0.051; Fig. 3.9c) and slightly lower levels brain amylin in
the Guanidine HCl-soluble fractions (P = 0.21; Fig. 3.9e), at the end of
treatment, compared to age-matched 18M UT rats. Levels of amylin in
independent plaques and mixed-plaques with Aβ were lower in treated groups
(Figs. 3.9f, 3.9h-i, Fig. S3.9). In addition, amylin depositions in brain capillaries
were lower in treated groups, compared to untreated rats (Figs. 3.9g and 3.9j).
In addition, the amylin WM-to-GM coverage ratio was lower in T-ES rats, but
not in rats received treatment at later stage (Fig. S3.8o)
Next, we compared markers of brain capillary and white matter injuries in
16M-UT vs. T-ES and 18M-UT vs. T-LS ADHIP rat groups. Histological analysis
of brain tissues showed a significant reduction in brain microhemorrhages in TES group (Fig. 3.9k). T-LS group also displayed a lower number of brain
microhemorrhages though not significant (Fig. 3.9k). Axonal myelination was
better preserved in the treated groups (Fig. 3.9l and Fig. S3.8p). Levels of
CD68 increased in the GM of T-ES but decreased in the WM of T-LS (Fig.
3.9m), suggesting changes in phagocytic microglia in response to BBB injuries
ameliorated by the treatments (Fig. 3.9k).
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These results show that peripherally mediated amylin dyshomeostasis
induced axonal degeneration as a result of progressive amylin deposition in
small blood vessels through mechanisms that appear to involve plaque
formation and microhemorrhages. Pharmacologically lowering amylin
deposition in the brain parenchyma and brain capillaries protected against
microhemorrhages and consequent brain white matter injury.
3.4. Discussion
By staining and imaging of amylin and Aβ in brain tissues from humans with
and without fAD, AD model rats with the pancreatic expression of amyloidforming human amylin, and AD model rats expressing non-amyloidogenic rat
amylin, we found that amylin accumulated in small blood vessels, paired with
Aβ in plaques and formed independent plaques and in space-filling lesion
within neurons. The results indicate amylin dyshomeostasis as a peripherally
mediated process that may contribute to the modulation of brain microvascular
and Alzheimer pathologies. Co-expressing amyloid-forming human amylin in
pancreatic islets and APPSwe/PS1DE9 in the brain in rats synergistically
accelerated neurological deficits. This was associated with brain amylin-Aβ
cross-seeding along with microhemorrhages and white matter changes. Similar
molecular processes were triggered by intravenous injection of human amylin
in APP/PS1 rats. These findings (summarized in Fig. 3.10) are of interest
because 1) a role of pancreatic amylin in the modulation of brain microvascular
and Alzheimer pathologies in fAD mutation carriers was previously unknown;
2) there is accumulating evidence (2-7, 99, 129, 193) showing brain amylin
deposition in the sporadic form of AD; 3) amylin deposition in tissues in humans
is associated with cell apoptosis (93) and inflammation (99, 123); and 4) blood
amylin may be a therapeutic target for slowing the progression of sAD and
improving the lives of fAD mutation carriers.
In sAD, brain amylin pathology was explained by hyperamylinemia (128),
as it coincides with hyperinsulinemia, a risk factor for sAD (200). We did not
anticipate amylin dyshomeostasis in fAD, given the earlier onset of the disease
with reduced age-dependence of amyloid pathology and insulin resistance.
What triggers brain amylin accumulation in fAD mutation carriers has yet to be
elucidated. It is intriguing that the brain amylin levels are higher in PSEN1 vs.
APP mutation carriers. Presenilins are present in the pancreatic β-cells (201);
whether the mutation of presenilin genes is a link between increased brain
amylin accumulation and fAD needs further investigation.
In human brains, amylin pathologies appeared more prevalent than Aβ
pathologies in white matter regions. This characteristic was mirrored in human
amylin-expressing AD rats and is consistent with our previous report indicating
axonal degeneration and late-onset neurological deficits in non-AD rats that
develop amylin dyshomeostasis (2, 8). Amylin crosses BBB with saturation at
physiological levels (64), and we found evidence of BBB injury and increased
brain amylin levels in response to high amylin in the periphery. We did find that
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acute “human” hyperamylinemia in young AD rats induced amylin accumulation
in the brain capillaries and brain hemorrhages, mirroring our findings in the
amylin-expressing AD rats. The results imply that high circulating levels of
amylin (common in patients with AD (193)) would lead to microvascular
dysfunction and disruption. They also imply that targeting fluctuation or peaks
of blood amylin level could reduce vascular amylin deposition, prevent amylin
from interacting with Aβ-associated pathology, and provide benefit in patients
with AD. The present results evoke a number of questions (How is amylin from
blood delivered to the brain parenchyma and cleared from brain tissues? Does
the amylin pathway change in response to AD? Is brain amylin delivery
potentiated by peripheral insulin resistance?), which are requisite for both a
basic understanding of amylin physiology and the rational design of amylincentered therapeutics.
It was proposed that circulating amylin clears Aβ peptide from the brain
(143) and that amylin analogs may protect the brain in human AD (193). If
amylin decreased Aβ pathology, we would then expect that overexpressing
human amylin in AD rats would slow disease progression, whereas the deletion
of the amylin gene would exacerbate AD pathology and behavior deficits. Our
results demonstrated the opposite and are consistent with data study showing
that human amylin administration in AD mice accelerated AD pathology (133).
Demonstrating that regulation of amylin homeostasis slows the progression
of AD is difficult because of a lack of anti-amylin drugs, but we showed that
suppression of amylin expression in AD rats is protective. This result has also
brought to light a potential paradoxical relationship between increased body fat
and effects on brain function in the setting of restricted amylin secretion.
Together, these findings suggest that amylin may play a critical role in energy
metabolism and brain function in ways more complex than initially considered.
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FIGURES

Figure 3.1. Brain amylin-Aβ composition in PSEN1 and APP mutation
carriers. (a) Amylin levels in temporal cortex specimens from PSEN1 and APP
mutation carriers (fAD; n = 18) and cognitively unaffected individuals (CU; n = 12).
(b, c) Representative images of immunohistological analysis using anti-amylin
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(brown) and anti-Aβ (green) antibodies on temporal cortex slices from fAD brains
(n = 27) and CU brains (n = 5). (d, e) Relative distribution of amylin amylin, Aβ and
amylin-Aβ calculated from immunohistological analysis of amylin and Aβ in the
grey matter plaques (left panel) in fAD brains (d; n = 27) and CU brains (e; n = 5).
See Methods section for image analysis. (f-l) In fAD brains (n = 27), amylin
deposition in neurons (f, g; arrowheads), or forming homogenous plaques (h, i)
and amylin-Aβ plaques (j-l) are shown. (m) Representative image of amylin and
Aβ depositions in CU brains (n = 5). (n) Confocal microscopic analysis of a fAD
brain section triple stained with Thioflavin S (ThioS, green), anti-amylin antibody
(red), and anti-Aβ antibody (magenta). Type of PSEN1 or APP mutation is labeled
on each image; 3 sections/brain. Scale bars, 200 µm (b, c), 50 µm (f-m), 10 µm
(n). Data are means ± SEM; P ≤ 0.01 **, P ≤ 0.001 ***, P ≤ 0.0001 ****; two-tailed,
unpaired t test with Welch’s correction.
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Figure 3.2. Brain amylin-Aβ vascular pathology in PSEN1 and APP mutation
carriers. (a, b) Representative images of immunohistological analysis using antiamylin (brown) and anti-Aβ (green) antibodies on temporal cortex slices from fAD
brains (n = 27) and CU brains (n = 5). (c) Estimated amylin-positive vs. Aβ-positive
areas in the white matter and grey matter of fAD brains (n = 27) and CU brains (n
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= 5). (d, e) Representative images of co-staining with anti-amylin (brown) and antiAβ (green) antibodies showing vascular amylin and Aβ deposits in a fAD brain (d)
and a CU brain (e). (f) Estimated area percentage of amylin in mixed amylin-Aβ
deposits in the blood vessels of individuals with PSEN1 (n = 20) or APP (n = 7)
mutation, and CU brains (n = 5). See Methods section for image analysis. (g-j)
Consecutive fAD brain sections stained with Congo Red (g), anti-Aβ (h), antiamylin (i), or a combination of anti-amylin and anti-Aβ (j) antibodies. (k-n) Confocal
microscopic analysis of a fAD brain section triple stained with Thioflavin S (ThioS,
green, k), anti-Aβ antibody (magenta, l), anti-amylin antibody (red, m). Type of
PSEN1 or APP mutation is labeled on each image; 3 sections/brain. Scale bars,
200 µm (a, b), 50 µm (d-e, g-j), 10 µm (k-n). Data are means ± SEM; P ≤ 0.05 *,
P ≤ 0.0001 ****; two-tailed, unpaired t test with Welch’s correction.
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Figure 3.3. Schematic summary of rat models generated for this study and
time points of behavior and molecular analyses. Genetic manipulation of
amylin expression was performed in rats with and without AD pathology through
transgenic expression of human amylin in the pancreas (red color code) and by
deletion of the amylin gene (light blue color code). The time points for behavioral
studies were chosen based on previous reports that amylin dyshomeostasis
develops at 12 months of age in human amylin expressing rats (HIP rats) and that
Aβ pathology is developed in APP/PS1 rats (AD rats) at about 16 months of age.
ADHIP rat: human amylin expressing Alzheimer disease model rat; AD rat:
Alzheimer disease model rat; HIP rat: human amylin expressing rat; WT rat: wildtype rat; AKO rat: amylin knock-out rat; AD-AKO: amylin knock-out Alzheimer
disease model rat; EETs: epoxyeicosatrienoic acids.
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Figure 3.4. Co-expression of amyloid-forming human amylin in the pancreas
and APPSwe/PS1DE9 in the brain accelerates neurological deficits in rats
(ADHIP rats). (a-f) Longitudinal average neurological scores of behavior tests for
motor function (assessed from forelimb use, balance ability on the inclined plane,
hind limb clasping, and Rotarod test) and cognitive function (assessed from the
novel object recognition and Morris water maze tests) in ADHIP vs. AD rats (n =
10 rats/group) (a-c); in HIP vs. WT rats (n = 10 rats/group) (d-f). Data for individual
tests are shown in Figures S3.3. (g) Schematic summary of results from (a-f). Data
are means ± SEM. P ≤ 0.05 *, P ≤ 0.01 **, P ≤ 0.001 ***, P ≤ 0.0001 ****; 2-way
ANOVA with Sidak post-hoc (a-f). ADHIP rat: human amylin expressing Alzheimer
disease model rat; AD rat: Alzheimer disease model rat; HIP rat: human amylin
expressing rat; WT rat: wild-type rat.
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Figure 3.5. Biomarkers of vascular endothelial injury in rats with pancreatic
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hypersecretion of amylin. (a-d) Representative images of co-staining with antiamylin (brown) and anti-Aβ (green) antibodies in brain sections in 16M old ADHIP
(a, b) and AD rats (c, d) (n = 5 rats/group). (e) Schematic of mechanisms tested
in the following experiments. (f, g) Representative images and analysis of brain
microhemorrhages stained with Prussian blue dye in 16M old ADHIP vs. AD rats
(f) and HIP vs. WT rats (g) (n = 5 rats/group). (h, l) Representative images and
analysis of marker for phagocytic microglia (CD68) (h) and vascular monocyte
recruitment (CD11b) (l) in brain sections from 16M old ADHIP vs. AD rats, HIP vs.
WT rats (n = 5 rats/group). (GM- grey matter; WM- white matter). Scale bars, 100
μm (a, c), 50 μm (b, d, h, i), 20 μm (f, g). Data are means ± SEM; P ≤ 0.05 *; twotailed, unpaired t test. ADHIP rat: human amylin expressing Alzheimer disease
model rat; AD rat: Alzheimer disease model rat; HIP rat: human amylin expressing
rat; WT rat: wild-type rat.
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Figure 3.6. Brain white matter changes in AD rats expressing human amylin

75

in the pancreatic islets (ADHIP rats) and microvascular injury in AD rats
intravenously infused with human amylin. (a) Slices 3 and 5 out of 7
consecutive slices of coronal T2-weighted MRI in brains of 16M old ADHIP and AD
rats (n = 6 rats/group). Arrowheads indicate the lateral side of hippocampus;
arrows indicate the temporal horns of lateral ventricles. (b) Volumes of ventricular
hyperintensity computed from MR images; 1 image pixel area = 0.024 mm2. (c)
Gross brain weights of 16M old ADHIP and AD rats (n = 10 rats/group). (d)
Representative images and analysis of brain myelin basic protein (MBP) in the
same rats as in (a) (n = 5 rats/group). (e) Intravenous infusion of human amylin in
AD rats. (f) Levels of amylin in the brain capillary lysates from human amylininjected AD rats vs. AD control rats (n = 5 rats/group). (g) Representative images
and analysis of brain microhemorrhages in human amylin-injected AD rats vs. AD
controls (n = 3 rats/group). Scale bars, 50 μm (d, f). Data are means ± SEM; P ≤
0.05 *, P ≤ 0.01 **; two-tailed, unpaired t test. ADHIP rat: human amylin expressing
Alzheimer disease model rat; AD rat: Alzheimer disease model rat; HIP rat: human
amylin expressing rat; WT rat: wild-type rat.
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Figure 3.7. Changes in brain and CSF Aβ associated with amylin-Aβ crossseeding in the brain. (a) CSF total Aβ levels in ADHIP vs. AD rats (n = 6-7
rats/group) at 12M and 16M of age. (b) Ratio of Aβ42-to-Aβ40 levels (Guanidine
HCl-fractions of brain homogenates) in 16M old ADHIP vs. AD rats (n = 6-7
rats/group). (c) Levels of amylin in the plasma of AD vs. ADHIP rats at 12M and
16M of age (n = 10 rats/group). (d) Brain amylin levels (Triton-fractions of tissue
homogenate) in 16M old ADHIP vs. AD rats (n = 7 rats/group). (e, f) Representative
immunohistological images of amylin (brown) and Aβ (green) depositions in brain
sections from 16M old ADHIP (e) and AD rats (f) (n = 5 rats/group). (g) Amylin
WM-to-GM coverage ratio on brain slices from 12M and 16M old ADHIP and AD
rats (n = 4-5 rats/group). (h) Levels of amylin in the plasma of HIP vs. WT rats at
12M and 16M of age (n = 10 rats/group). (i) CSF total Aβ levels in HIP vs. WT rats
(n = 3 rats/group) at 12M and 16M of age. (j) Brain amylin levels (Triton-fractions
of tissue homogenate) in 16M old HIP vs. WT rats (n = 7 rats/group). (k, l)
Representative immunohistological images of amylin (brown) and Aβ (green)
depositions in brain sections from 16M old HIP (k) and WT rats (l) (n = 5
rats/group). (m) Amylin WM-to-GM coverage ratio on brain slices from HIP and
WT rats (n = 5 rats/group). (n) Summary of results from testing hypothesis from
Figs. 3.4-3.7. Scale bars, 200 μm (e, f, k, l). Data are means ± SEM; P ≤ 0.05 *, P
≤ 0.001 ***, P ≤ 0.0001 ****; two-tailed, unpaired t test. ADHIP rat: human amylin
expressing Alzheimer disease model rat; AD rat: Alzheimer disease model rat; HIP
rat: human amylin expressing rat; WT rat: wild-type rat.
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Figure 3.8. Suppressed pancreatic expression of amylin reduced
neurological deficits and amylin-Aβ cross-seeding in the brains of
APPSwe/PS1DE9 rats. (a-d) Representative immunohistological images of costaining with anti-amylin (brown) and anti-Aβ (green) antibodies in brain sections
from 16M old ADHIP (a), AD (b), HIP (c) and WT (d) rats (n = 5 rats/group). (e-h)
Representative immunohistological images of staining with anti-amylin (brown)
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antibody in pancreas sections from the same rats as in (a-d). (i-k) Representative
images of immunostaining for amylin and Aβ in brain tissues from 16M old AD rats
with deleted amylin genes (AD-AKO rats) (n = 5 rats/group). (l) Representative
images of immunostaining for amylin in pancreas tissues from the same rats as in
(i-k). (m) Counts of mixed amylin-Aβ plaques (i.e., amylin-core Aβ plaques) in AD
and AD-AKO rat brains assessed from immunohistological images (n = 5
rats/group) (data were normalized to total imaging area). (n-p) Longitudinal
average neurological scores of behavior tests for cognitive function (assessed from
novel object recognition test) and motor function (assessed from forelimb use and
hind limb clasping tests) in AD rats vs. AD-AKO rats at 8, 12 and 16 months of age
(n = 9 rats/group) (see also Fig. S3.7). (q) Longitudinal average body weights of
AD rats vs. AD-AKO rats (n = 9 rats/group). Data are means ± SEM. P ≤ 0.05 *, P
≤ 0.01 **, P ≤ 0.0001 ****; two-tailed, unpaired t test (m); 2-way ANOVA with Sidak
post-hoc (n-p); 2-way ANOVA (q). ADHIP rat: human amylin expressing Alzheimer
disease model rat; AD rat: Alzheimer disease model rat; HIP rat: human amylin
expressing rat; WT rat: wild-type rat; AD-AKO: amylin knock-out Alzheimer disease
model rat.
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Figure 3.9. Pharmacologically ameliorated amylin dyshomeostasis improves
functionality of human amylin-expressing AD rats. (a) Diagram of
pharmacological interventions to ameliorate early stage and late-stage amylin
dyshomeostasis in ADHIP rats using a soluble epoxide hydrolase inhibitor (sEHi).
(b) Neurological score (z-score) of behavioral tests (cognitive function and motor
function; see also Fig. S3.8) in the sEHi early-stage treated ADHIP rats (T-ES) vs.
age-matched untreated (UT-ES) rats (n = 5 rats/group); in the sEHi late-stage
treated ADHIP rats (T-LS) vs. age-matched untreated (UT-LS) rats (n = 6
rats/group). (c) Amylin levels in the plasma from 16M T-ES vs. UT-ES rats (n = 5
rats/group) and 18M T-LS vs. UT-LS rats (n = 6 rats/group). (d, e) Amylin levels in
the brain homogenates (Triton and Guanidine HCl-soluble fractions) from 16M TES vs. UT-ES rats (n = 5 rats/group, d) and 18M T-LS vs. UT-LS rats (n = 6
rats/group, e). (f) Representative immunohistological images for amylin and Aβ in
the parenchymal plaques of 16M T-ES vs. UT-ES rats (n = 5 rats/group) and 18M
T-LS vs. UT-LS rats (n = 3-6 rats/group). (g) Representative immunohistological
images for amylin in the brain capillaries of 16M T-ES vs. UT-ES rats (n = 5
rats/group) and 18M T-LS vs. UT-LS rats (n = 3-6 rats/group). (h-j) Analysis of total
plaques deposition (h), number of mixed amylin-Aβ plaques (i), and amylin in the
luminal vascular deposition (j). (k-m) Representative images of histological
analysis of brain microhemorrhages (k), myelin basic protein (MBP) (l), and
macrophage marker (Cluster of differentiation 68, CD68) (m) in brain sections from
16M T-ES vs. UT-ES rats (n = 5 rats/group) and 18M T-LS vs. UT-LS rats (n = 36 rats/group). Scale bar, 50 µm (f, g, m), 20 µm (k), 100 µm (l) (GM-grey matter;
WM-white matter). Data are means + SEM; P < 0.05 *, P < 0.01 **, P ≤ 0.0001 ****;
2-way ANOVA with Sidak post-hoc (b); two-tailed, unpaired Student’s t test (c-e,
h-m). ADHIP rat: human amylin expressing Alzheimer disease model rat.
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Figure 3.10. Schematic summary of the results and proposed mechanism.
Circulating amylin affects brain and CSF Aβ levels via amylin-Aβ cross-seeding
and brain amylin accumulation that induces microvascular injuries and white
matter changes. Pharmacological lowering of blood amylin decreases amylin-Aβ
cross-seeding and brain amylin accumulation. Amylin gene deletion in APP/PS1
rats blocks amylin accumulation in the brain and amylin-Aβ cross-seeding,
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providing protection against AD-related behavior changes. ADHIP rat: human
amylin expressing Alzheimer disease model rat; AD rat: Alzheimer disease model
rat; HIP rat: human amylin expressing rat; WT rat: wild-type rat; AD-AKO: amylin
knock-out Alzheimer disease model rat.
.
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SUPPLEMENTAL TABLES AND FIGURES
Table S3.1. Neuropathological information, age and sex of patients included
in the study in Chapter 3.
Top: Numbers of familial AD brains with different amylin and Aβ pathologies that
were assessed by immunohistochemical analysis. The total number of human
brains analyzed is 27.
Bottom: Neuropathological information, age, and sex for individuals with cognitive
unaffected (control), familial AD, or sporadic AD included in the present study.
Familial AD brain pathology
Mixed amylin-Aβ plaques in tissue parenchyma
Mixed amylin-Aβ plaques in blood vessels
Amylin plaques
Amylin-positive neurons
Cognitive
unaffected (CU)
n = 5 (for fAD)
n = 3 (for sAD)

Patients/total (%)
17/27 (63%)
22/27 (81%)
16/27 (59%)
26/27 (96%)

Familial AD Sporadic
(fAD)
(sAD)

Histological
analyses
Gender, female/male
(% female)
2/1 (67%) (for sAD)
Age at death (avg +
SEM)
84.7 ± 2.3 (for sAD)
Braak stage
N.A.
Mutation, PSEN1/APP N.A.
Cognitive
unaffected (CU)
Amylin ELISA
n = 12
Gender, female/male
(% female)
11/1 (92%)
Age at death (avg +
SEM)
88.4 ± 2.0
Braak stage
0-IV
Mutation, PSEN1/APP N.A.

n = 27

n=6

17/10 (63%)

4/6 (67%)

54.2 ± 1.8
V-VI

89.8 ± 2
V-VI

20/7
N.A.
Familial AD
(fAD)
n = 18
12/18 (67%)
54 ± 2.4
V-VI
11/7

85

AD

Table S3.2. Analysis of associations of the amylin gene variants with the risk
for developing AD.
Top: Loss of function gene variants in amylin (islet amyloid polypeptide; IAPP)
present in gnomAD and respective ages. Loss of function variants with a
consequence in the canonical transcript of IAPP and without quality flags in
gnomAD. *Age information available for 2 individuals. #CHR: Chromosome; Ref.:
Reference; Alt.: Alternate; Trans. Cons.: Transcript consequence. AC: Allele
count; Allele Freq.: Allele frequency.
Bottom: Association results from the IGAP consortium for IAPP variants. #CHR:
Chromosome; POS: position of the SNP (Build 37, Assembly Hg19); MarkerName:
SNP rsID; Effect_allele: reference allele (coded allele); Non_Effect_allele: non
reference allele; Beta: overall estimated effect size for the effect allele; SE: overall
standard error for effect size estimate; P: meta-analysis P-value using regression
coefficients (beta and standard error).
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Table S3.2. (continued)
#CH
R
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12

POS
21526443
21526472
21526651
21526883
21527044
21527681
21527955
21528337
21529150
21529212
21529687
21529882
21530485
21531437
21532100
21532138
21532191
21532217
21532459
21532547

MarkerName Effect
allele
rs41275208
A
rs12306121
G
rs12319824
A
rs12300126
C
rs73080823
T
rs17680758
G
rs12308285
T
rs12811082
T
rs17680787
T
rs12305367
C
rs34417126
C
rs34996992
C
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A
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Beta

SE

P

-0.0448
-0.044
-0.0425
-0.0421
-0.0452
-0.0319
-0.0352
-0.0415
-0.0437
-0.0507
-0.046
-0.0476
-0.0405
-0.0437
-0.0454
-0.0471
0.1076
-0.0515
-0.0358
-0.0474

0.0362
0.0197
0.0199
0.0203
0.0362
0.0314
0.0193
0.0217
0.0208
0.0201
0.0204
0.0203
0.0365
0.0205
0.0361
0.0209
0.0579
0.0201
0.0383
0.0199

0.2159
0.02536
0.0326
0.03793
0.2124
0.309
0.06842
0.05627
0.03531
0.01168
0.02398
0.01902
0.2661
0.0333
0.2087
0.02439
0.06315
0.01039
0.3504
0.01742

Figure S3.1. Brain amylin pathology in PSEN1 and APP mutation carriers,
and in patients with sporadic AD. (a) Example of amylin deposition in the
pancreatic tissue from a patient with type 2 diabetes (positive control for amylin
deposition in human tissue). (b) Amylin levels in human brain homogenates from
PSEN1 mutation carriers (n = 11) and APP mutation carriers (n = 7) vs. CU
individuals (n = 12). (c) Representative confocal microscopy analysis of brain
tissue from a patient with fAD (PSEN1 intron 4) double-stained with anti-amylin
antibody (green) and anti-p-tau antibody (red). (d) Representative confocal
microscopy analysis of brain tissue from a patient with sporadic AD double-stained
with anti-amylin antibody (green) and anti-Aβ antibody (red). Nuclei are stained
blue. Scale bars, 100 μm (a), 10 μm (c, d). Data are means ± SEM; P ≤ 0.05 *; P
≤ 0.001 ***; two-tailed, unpaired t test with Welch’s correction.
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Figure S3.2. Brain amylin pathology in the white matter of fAD patients.
Typical characteristics of amylin-associated pathology in the white matter regions
of fAD brains, including amylin deposition in old infarct areas (arrows), perivascular
region (arrowheads) and diffusive plaques (double arrowheads). The
representative image is from fAD brain with mutation in PSEN1 I202F.
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Figure S3.3: Motor function deficits in AD and non-AD rats with pancreatic
expression of human amylin. Measurements of forelimb use (a, e), balance
ability on the inclined plane (b, f), hind limb clasping (c, g) and Rotarod test (d, h)
at 8M, 12M and 16M of age in ADHIP, AD, HIP and WT rats. ADHIP rats were
compared to AD littermates (n = 10 rats/group) (a-d). HIP rats were compared to
WT littermates (n = 10 rats/group) (e-h). Data are means ± SEM. P ≤ 0.05 *, P ≤
0.01 **; two-tailed, unpaired t test (a, b, e, f); Mann-Whitney test (c, g); mixedmodel ANOVA (because of missing values from non-performing animals) with
Sidak post-hoc (d, h). Non-performing animals on the Rotarod test (see text in
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Methods) were excluded from the analysis. ADHIP rat: human amylin expressing
Alzheimer disease model rat; AD rat: Alzheimer disease model rat; HIP rat: human
amylin expressing rat; WT rat: wild-type rat.
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Figure S3.4. Effects of increased circulating amylin on cognitive function in
AD and non-AD rats with pancreatic expression of human amylin. Results of
novel object recognition test (a, d) and the percentage of time spent in the target
quadrant in the Morris water maze test on learning trials (b, e) and probe trials (c,
f) at 8M, 12M and 16M of age in ADHIP, AD, HIP and WT rats. ADHIP rats were
compared to AD littermates (n = 10 rats/group) (a-c). HIP rats were compared to
WT littermates (n = 10 rats/group) (d-f). Data are means ± SEM. P ≤ 0.05 *; twotailed, unpaired t test (a, c, d, f mixed-model ANOVA (because of missing values
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from non-performing animals) with Sidak post-hoc (b, e). Non-performing animals
on the water maze test (see text in Methods) were excluded from the analysis.
ADHIP rat: human amylin expressing Alzheimer disease model rat; AD rat:
Alzheimer disease model rat; HIP rat: human amylin expressing rat; WT rat: wildtype rat.
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Figure S3.5. Brain white matter demyelination in ADHIP, AD, HIP, and WT
rats. Representative images and analysis of brain white matter demyelination with
luxol fast blue in the same rats as in Figs. 3.5a-d (n = 5 rats/group). Scale bars, 50
µm. Data are means ± SEM. P ≤ 0.01 **; Mann-Whitney test. ADHIP rat: human
amylin expressing Alzheimer disease model rat; AD rat: Alzheimer disease model
rat; HIP rat: human amylin expressing rat; WT rat: wild-type rat.
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Figure S3.6. Plaques deposition in the brain of AD and non-AD rats with
pancreatic expression of human amylin; Amylin-Aβ cross-seeding induced
by intravenous infusion of human amylin in young AD rats. (a) Representative
immunohistochemical images of amylin (brown)-Aβ (green) plaques in the
hippocampus of ADHIP, AD, HIP, and WT rat brains (n = 5 rats/group). (b)
Estimated percentage of area stained positive for amylin in the hippocampal
plaques of ADHIP, AD, HIP and WT rat, assessed from immunohistological images
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(n = 5 rats/group). (c) Plasma amylin levels in AD rats intravenously infused with
human amylin and age matched AD control rats after injections (n = 5 rats/group).
(d) Neurological scores calculated from behavior tests for cognitive function and
motor function in AD-amylin injected rats vs. AD-controls (n = 5 rats/group). (e)
Representative immunohistological images of amylin (brown) and Aβ (green)
showing amylin-Aβ plaques (arrow) and amylin accumulation in neurons (circles)
(n = 3 rats/group). Scale bars, 200 µm (a), 50 µm (e). Data are means ± SEM; P ≤
0.05 *; two-tailed, unpaired t test. ADHIP rat: human amylin expressing Alzheimer
disease model rat; AD rat: Alzheimer disease model rat; HIP rat: human amylin
expressing rat; WT rat: wild-type rat.
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Figure S3.7. Suppression of amylin gene in AD rats slows cognitive
dysfunction. (a-c) Novel object recognition (a), forelimb use (b), and hind limb
clasping (c) of AD rats vs. AD rats with deleted amylin genes (AD-AKO rats) at 8,
12 and 16 months of age (n = 8-9 rats/group).Data are means ± SEM; P ≤ 0.01 **;
two-tailed, unpaired t test. AD: Alzheimer disease model rat; AD-AKO: amylin
knock-out Alzheimer disease model rat.
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Figure S3.8. Pharmacologically ameliorated amylin dyshomeostasis
improves neurological function of human amylin-expressing AD rats. (a-m)
Hind limb clasping test (a, h), inclined plane test (b, i), forelimb use test (c, j),
rotarod performance (d, k), novel object recognition (e, l) and performance in water
maze test (f, g, m, n) in sEHi early-stage treated ADHIP rats (T-ES) vs. age98

matched untreated (UT-ES ) rats (n = 5 rats/group) (a-g); in the sEHi late-stage
treated ADHIP rats (T-LS) vs. age-matched untreated (UT-LS ) rats (n = 6
rats/group) (h-n). (o) Amylin WM-to-GM coverage ratio on brain slices from 16M
T-ES vs. UT-ES rats (n = 5 rats/group) and 18M T-LS vs. UT-LS rats (n = 6
rats/group). (p) Representative histological images and analysis for white matter
demyelination in the brains of 16M T-ES vs. UT-ES rats (n = 5 rats/group) and 18M
T-LS vs. UT-LS rats (n = 3-6 rats/group). Scale bar, 100 µm (p). Data are means
+ SEM; P < 0.05 *; Mann-Whitney test (a, h, p); two-tailed, unpaired Student’s t
test (b, c, e, g, I, j, l, n, o); 2-way ANOVA with Sidak post-hoc (d, f, k, m). ADHIP
rat: human amylin expressing Alzheimer disease model rat.
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Figure S3.9. Pharmacologically ameliorated amylin dyshomeostasis
decreases amylin-Aβ cross-seeding in human amylin-expressing AD rats.
Representative immunohistological images of amylin (brown) and Aβ (green)
showing amylin-Aβ plaques in the brains of 16M T-ES vs. UT-ES rats (n = 5
rats/group) and 18M T-LS vs. UT-LS rats (n = 3-6 rats/group). Scale bar, 200 µm.
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CHAPTER 4. CONCLUDING REMARKS
4.1. Summary
Investigations of human brain tissues and rodent models expressing human
amylin in the pancreas suggest that amylin dyshomeostasis is a contributing
factor to the pathology and progression of the cerebrovascular disease (CVD)
and Alzheimer disease (AD). Amylin from the pancreas accumulates in the
brains of AD patients with or without T2D (2-7, 99, 129). Additionally, amylin
accumulation is abundant in the cerebral small vessels and co-localizes with
Aβ in cerebral amyloid of AD patients with or without T2D (2, 5, 129) and of
patients with familial AD (Chapter 3). Amylin depositions were found in the brain
parenchyma as independent plaques or as mixed plaques with Aβ in both
sporadic and familial forms of AD ((5, 6, 129) and Chapter 3). Interestingly,
intracellular amylin accumulation was detected in neurons (99), pericytes (4),
astrocytes (129), and microglia (129). And such accumulation is associated
with changes in cellular metabolism and viability (4, 99), impeding proper
cellular functioning. The results suggest a role of amylin dyshomeostasis in
brain microvascular pathologies and AD.
This chapter is focused on future research directions related to mechanisms
of amylin-mediated pathological processes in CVD and AD.
4.2. Gap of knowledge and future directions for laboratory studies
(Refer to Figure 4.2 for the schematic summary of the cellular and molecular
mechanisms proposed in this section)
4.2.a. Studies on the mechanisms of cerebrovascular pathology
mediated by peripheral amylin
4.2.a.i Proposed investigations on the mechanisms of
transporting amylin from the circulation into the brain
1. Molecular and cellular carriers of amylin in the circulation
Cerebral or cerebrovascular accumulation of amylin may require carrier(s)
in the circulation. Carrier(s) could be macro-/micro-molecules or cellular
components in the circulation. Several lines of evidence mentioned below have
prompted us to speculate that amylin interaction with other molecules or cellular
components in the circulation may initiate pathological changes in those
molecules/components important for physiological functions.
1.a. Molecular and cellular carriers of amylin in the circulation: plasma
apolipoproteins
One of our studies has identified several forms of apolipoprotein
(apolipoprotein E and apolipoprotein A) that interact with, and potentially carry,
amylin in the circulation (2). Apolipoprotein (APOE) is a plasma protein
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produced primarily by the liver and macrophages in the periphery and also by
the brain (190). APOE serves as a ligand for low-density lipoprotein receptor
and participates in the transport of cholesterol and other lipids among various
cells of the body (190). There are three major isoform of human APOE—
APOE2, APOE3, and APOE4 — differ by single amino acid interchanges at two
residues that affects their binding to apolipoprotein receptors, lipids and Aβ
(202). The APOE4 gene strongly associates with the pathology and clinical
outcome of late-onset familial and sporadic AD (203-206). APOE4 is also
associated with an increased risk of cerebral amyloid angiopathy and agerelated cognitive decline in normal aging (202). APOE4 affects extensive
pathological processes associated with AD, including impaired neuronal
structure and function, neuronal mitochondrial dysfunction, increased Aβ
production, altered Aβ peptide clearance and/or deposition, and impaired
cognitive function in mice (207).
Recent studies found APOE in amylin amyloid-containing pancreatic tissue
from humans (169, 171). The infusion of APOE4, an isoform of APOE,
exacerbated amylin-mediated capillary injury and brain amylin accumulation in
human amylin expressing (HIP) rats (2). These results suggest that the
interaction between amylin and plasma APOE is a potential mechanism
underlying brain amylin pathology. APOE4 binds to amylin strongly and
facilitates amylin aggregation in the pancreas of T2D patients (169), thus we
speculate that the elevated level of plasma APOE4 could trigger toxic amylin
aggregates formation in the blood, increasing the amount of toxic amylin
aggregate entering the brain. Intriguingly, a recent study points out that different
isoform of APOEs bind and inhibit toxic amylin aggregate formation, protecting
the brain vascular pericyte (208). Among three isoform, APOE4 has the
weakest protective effect on vascular pericyte because of its lower ability to
inhibit toxic amylin aggregate formation (208). Because APOE4 is a strong risk
factor for AD development, the findings that APOE4 affects amylin aggregation
(169, 208) and amylin-mediated capillary injuries (2, 208) suggest an
interaction between amylin and the development of AD. Additional studies are
still needed to test the potential role of APOE alleles in promoting vascular
amylin deposition, how APOE-amylin complex interacts with receptors,
particularly low-density lipoprotein receptors (LDL-R) on the vascular
endothelium, and promotes amylin accumulation and translocation to the brain,
resulting in vascular injuries.
1.b. Molecular and cellular carriers of amylin in the circulation: red blood
cells
Erythrocytes or red blood cells (RBCs) deliver oxygen to cells and tissues
in the body and carry carbon dioxide waste to the lungs. In patients with T2D,
the oxygen-carrying capacity of RBCs declines, exacerbating the risk for
hypoxia-induced tissue damage and microvascular complications, including
cerebrovascular disease (209, 210). We found aggregated amylin in RBCs
from T2D rats and humans with diabetic complications (97). In humans, amylin
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deposition in RBCs is associated with T2D, heart failure, cancer, and stroke
(97). The concentration of amylin in RBC lysates from individuals with a primary
diagnosis of T2D (without heart failure, cancer, or stroke) is higher than those
from healthy individuals and patients with type 1 diabetes. Patients with a
primary diagnosis of heart failure, cancer, or stroke also have elevated RBC
amylin levels independent of T2D (97). These clinical data pose a hypothesis
that elevation of circulating amylin is linked to cardiovascular and microvascular
dysfunction. Further experiments in HIP rats suggested that amylin deposition
in RBCs may cause of RBC shape change, reduced functional hemoglobin,
increased RBC attachment to the vascular endothelium, and renal
microvascular ischemic-hypoxic injuries even before the onset of overt
hyperglycemia (97). The morphological changes in RBC from amylin deposition
potentially hinder RBC function, thus affecting cellular metabolism in many
organs; for example, the brain (2, 8, 99) and the kidney (97). The finding that
RBC as a carrier for circulating amylin is important because it could serve as a
molecular link between pancreatic dysfunction and diabetic-related
microvascular complications, and as a biomarker for early detection (before the
onset of hyperglycemia) of diabetes-related end-organ damage.
Yet, much work is still needed to elucidate the mechanisms in which amylin
deposits on the RBC membrane and how it affects hemoglobin binding to
oxygen, as deformities in RBC decreases oxygen binding with hemoglobin
(211). The accumulation of amylin on the RBC membrane and amylin-mediated
RBC membrane disruption are consistent with previous studies on amylin
harmful effects on the plasma membrane of other cell types including
pancreatic β-cell (107) and neurons (99, 141). The proposed mechanisms for
amylin-membrane interaction and membrane disruption are pore formation
(107-110) and damage from fibril growth (104, 107), which could be challenging
to study and to develop therapeutic strategies as the amyloid formation on the
cellular membrane is not fully understood (212). Hence, a more feasible route
is to test for potential receptors on RBC for amylin ligand binding (Fig. 4.2).
Indeed, published research shows that human amylin is recognized by receptor
CD36 on the macrophage surface, then is engulfed by macrophages to trigger
inflammatory responses (151). Interestingly, CD36 is also present on the RBC
membrane and is important for RBC adhesion to endothelial cells (213). It will
be beneficial to test whether this receptor and others on the RBC bind to amylin
and facilitate downstream signaling responding to the toxic amyloid
accumulation, including injuries to the RBC-capillary interaction. This could
lead to hypoxia-induced brain damage, which is currently proposed as one of
the mechanisms that facilitate AD (214).
1.c. Molecular and cellular carriers of amylin in the circulation: white blood
cells
Along with RBCs, white blood cells may be cellular carriers as amylin is also
detected in the white blood cells lysate from patients with T2D in our study (97).
This is a feasible hypothesis because white blood cells protect the body from
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infectious disease and harmful substances; and toxic amylin aggregate is a
target for macrophage endocytosis, as previously reported (151). There are
several primary questions regarding this topic that we need to answer. First, is
the endocytosis of amylin aggregates by white blood cells important to
decrease amylin amyloid accumulation in the circulation? If yes, how efficient
is this process in normal individuals compared to diabetic ones? Second, when
does the inflammatory response triggered by the endocytosis of amylin become
harmful to surrounding tissues? Third, do white blood cells inadvertently
become carriers of engulfed amylin because of their ability to infiltrate to other
organs during inflammatory responses? Therefore, future investigations on
cellular carriers of amylin in the circulation are needed to identify therapeutic
targets to prevent amylin accumulation in extra-pancreatic organs, including
the brain.
2. Identify the mechanism of amylin release at the brain
endothelium
Since amylin is from the periphery, the translocation of amylin from the
blood vessels to the parenchyma may require adhesion of cellular/molecular
carriers and protein transporters. Likely, such translocation is concentrationdependent, because a high concentration of aggregated amylin induces
endothelial apoptosis (2). Following the assessment of the cerebrovascular
injury in the animal model of amylin dyshomeostasis, in vitro studies designed
to identify specific adhesion mechanisms and protein transporters are
important steps to decipher how amylin interacts with the blood-brain barrier
units and its translocation mechanisms.
In the kidney of HIP rats, vascular amylin accumulation associates with
vascular damage, inflammatory, and hypoxia response (97). These effects are
partly mediated by amylin-loaded RBCs (97). Amylin-loaded RBCs from HIP
rats are more adhesive to the endothelium than RBCs from wild-type rats (97),
and this effect seems to involve the upregulation of vascular cell adhesion
molecule 1 on the endothelium. However, the specific mechanism of the
increased RBC adhesion to the vascular endothelium remains elusive.
RBC adhesion to the EC layer is regulated by the macromolecules such as
glycocalyx on the endothelium (215). The endothelial glycocalyx is a thick
carbohydrate-rich layer lining the luminal side of the vascular endothelium
(216). It consists of membrane-bound and soluble molecules components. The
membrane-bound component is mainly composed of proteoglycans and
glycoproteins binding to the EC surface (216). The soluble molecules are
plasma- or endothelium-derived soluble molecules, integrating on top of the
membrane-bound component (216). Research shows that glycocalyx is
fundamental in microcirculation (215, 216). The depletion of EC glycocalyx is
important in enhancing blood cells attached to the luminal wall of the
endothelium (215). Glycocalyx shedding is shown to respond to ischemiareperfusion injury, hyperglycemia, and inflammation (215). Interestingly, T2D is
associated with glycocalyx perturbation and increased vascular permeability
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(217), and treatment with oral glycocalyx precursor for 2 months partially
restores glycosaminoglycan synthesis and vascular permeability in T2D
patients (217). From here, we hypothesize that the aggregation of amylin on
the membrane RBCs (97) and vascular ECs (2) deplete the glycocalyx layer on
EC, which enhances RBCs adhesion onto the vascular ECs, therefore
promoting amylin release into the brain vessels (Fig. 4.2). Restoring EC
glycocalyx could alleviate amylin-mediated microvascular injury.
Going from here, the steps are to understand whether the translocated
amylin in the brain affects (a) the function of the neurovascular components in
controlling blood-brain barrier function and cerebral perfusion; (b) the dynamic
of the clearance and accumulation of amyloid proteins in the brain such as Aβ.
4.2.a.ii Proposed investigations on the mechanisms of amylinmediated blood-brain barrier injuries affecting vascular
function
The blood-brain barrier (BBB) is a dynamic multicellular vascular structure
presented at all blood vessels within the central nervous system (CNS). The
BBB separates the CNS from the systemic circulation and maintains a
microenvironment for neurons to function properly by facilitating nutrients and
oxygen uptake, protecting the brain from toxins and pathogens, extruding
metabolic products and toxins (218-220). The barrier is formed by capillary
endothelial cells, ensheathed by the basal lamina, pericytes, astrocytic
perivascular end-feet, microglia, and a basement membrane made from
collagen and laminin. The principal component of the barrier function is
capillary ECs interconnected by tight-junctions (221). Growing evidence
suggests that astrocyte secretes many factors for BBB formation, maintenance,
function, and repair; interacts with other ECs for tighter physical barrier (222,
223). In response to CNS injury, astrocytes undergo a defensive reaction or
reactive astrogliosis that associates with progressive cellular hypertrophy; in
the severe case, proliferation and scar formation (222). The deleterious
consequences are the loss of their physiological supportive functions, BBB
disturbance, cytokine over-release, and oxidative stress (224). Therefore, both
endothelium and astrocyte dysfunction can lead to the breakdown of the BBB.
The BBB disruption may initiate and/or contribute to the progression of white
matter hyperintensities (WMH) and dementia (161, 225). In the brains of HIP
rats (rats that express amyloidogenic human amylin in the pancreas), we found
that amylin deposits in small arteries and capillaries, and such accumulation
associates with decreased cerebral blood flow and WMH (2). Accumulation of
amylin in the capillaries causes a decline in levels of endothelial tight-junction
proteins, endothelium disruption, and astrogliosis (2). In contrast, age- and
blood glucose-matched diabetic rats, which express non-amyloidogenic rat
amylin, show no amylin deposition in the brains (99). Our studies show that
circulating aggregated amylin plays a critical role in lesions, including BBB
breakdown. From these results, we next postulate that the mechanisms
underlying deep white matter capillary lesions and impaired cerebral blood flow
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involve amylin-mediated (a) endothelial dysfunction and (b) astrocyte
hypertrophy and inflammatory signaling activation, via calcium dysregulation,
leading to BBB damage and vascular dysfunction.
1. Endothelial cell injuries and endothelial dysfunction
Clinical studies suggest that both T2D and AD are associated with brain
insulin resistance (226). Brain insulin resistance and relevant vascular
dysfunction in T2D could heighten the risk for AD (227). Vascular dysfunction
in T2D patients is associated with impaired insulin signaling in ECs (228-230),
but the direct molecular link between T2D and EC impaired insulin-mediated
vasoregulation remains elusive. The vascular endothelium plays a critical role
in regulating BBB permeability, cerebral blood flow, and nutrient delivery to
surrounding tissues (231). In response to hormones, neurotransmitters and
stimuli, endothelium ensures even blood flow through acute vasoregulation.
Acute vasoregulation is achieved through the endothelial production of
vasodilators such as nitric oxide (NO), and vasoconstrictors such as
endothelin-1 (ET-1) (232). Insulin can contribute to vasoregulation as it induces
NO and ET-1 release from ECs through PI3K and MAPK pathways,
respectively (233). NO and ET-1 released from ECs regulate vascular smooth
muscle cells activity, thus contributing to cerebral blood flow regulation (230,
233). In normal individuals, the vasodilation and vasoconstriction effects of
insulin are in balance. In individuals with insulin resistance, the insulinmediated vasodilation becomes defective, characterized by a reduction in
basal and insulin-stimulated NO production by the endothelial nitric oxide
synthase (eNOS), leading to augmented vasoconstriction from ET-1 action
(230, 234, 235). This endothelial dysfunction disables normal vasomotion and
contributes to stroke progression (236). Up to date, the cause of endothelial
dysfunction in T2D remains unclear. From our previous study, we found that
the high level of amylin in the blood (hyperamylinemia) promotes amylin
deposition in the cerebral blood vessels, leading to EC injuries and is
associated with decreased cerebral blood flow (2). In the kidney of HIP rats,
amylin accumulation in the capillaries triggers hypoxia response which can
affect downstream NO production (97), suggesting that high levels of circulating
amylin can contribute to change in blood flow. From these results, we postulate
that aggregated amylin contributes to blood flow alteration in the brain may
involve changes in insulin-mediated vasoactive mediators’ production. We
hypothesize that aggregated amylin impairs insulin-mediated NO production in
cerebrovascular ECs, contributing to EC dysfunction and decrease cerebral
blood flow regulation.
The insulin signaling in vascular endothelium regulates eNOS activation by
PI3K/AKT phosphorylation-dependent mechanism (233). The PI3K pathway is
important in mediating insulin-stimulated production of NO in the endothelium
(237) in which the tyrosine phosphorylation of insulin receptor substrate-1 (IRS1) is required (238). PI3K activates AKT, and AKT directly phosphorylates
eNOS at Ser1177(239), resulting in enhanced NO production. In T2D, impaired
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insulin signaling prevents eNOS phosphorylation and NO release from ECs,
inducing EC dysfunction. The role of amylin in endothelial insulin-mediated
vascular tone has not been characterized. The finding that HIP rats developed
peripheral insulin resistance (8, 95) and had amylin deposition on the brain EC
(2) lead us to speculate that aggregated amylin may interact with the insulin
receptor and/or impede the insulin-stimulated NO release machinery. To test
the above hypothesis, it is important to first understand whether aggregated
amylin impairs insulin-mediated NO production by inhibiting PI3K/AKTdependent eNOS activation. We propose to test the following hypotheses (Fig.
4.2.a.ii.1): (a) aggregated amylin interacts with insulin receptor on EC, (b)
aggregated amylin inhibits phosphorylation of IRS-1, AKT and eNOS and (c)
inhibits the production of NO preventing EC dilation.
Second, we will need to characterize aggregated amylin role in calciumdependent eNOS activation, specifically test if aggregated amylin inhibits
eNOS activation by inhibiting CaMKII-dependent eNOS activation and
promoting PKCβ activity (Fig. 4.2.a.ii.1). eNOS activation requires
simultaneous phosphorylation by Ca2+/calmodulin-dependent protein kinase II
(CaMKII) (240) and dephosphorylation modulated by protein kinase C β
(PKCβ) activity (241, 242). CaMKII, a multifunctional serine/threonine-protein
kinase, is critical in transducing of increased intracellular Ca2+ by binding to
Ca2+/calmodulin (CaM) complex (243). CaMKII is expressed in vascular EC
(244) and participates in Ca2+-dependent eNOS activation (240). PKCβ is a
calcium-dependent kinase responsible for eNOS negative regulation. T2D
patients exhibit higher PKCβ expression associated with lower blood flowmediated dilation (241). From previous studies discussed in Chapter 1, we
know that aggregated amylin is cytotoxic because it disrupts the cellular
membrane and causes calcium dyshomeostasis (122, 245-247). Thus, we
speculate
that
amylin-attenuated
eNOS
phosphorylation
and
dephosphorylation are achieved through Ca2+ dysregulation. To solve the
question of aggregated amylin involvement in both regulation stages of eNOS
signaling, we propose to test the following hypotheses: (a) amylin-induced Ca2+
dysregulation inactivates CaMKII-mediated eNOS phosphorylation, (b) amylin
enhances PKCβ activity, thus preventing eNOS dephosphorylation, (c)
prevention of amylin deposition on cellular membrane could restore eNOS
function.
The results will provide insight into vascular complications from T2D. If our
hypothesis is true, then hyperamylinemia could promote endothelial cells
dysfunction, specifically through impairing insulin-stimulated NO production.
NO has important functions in oxidative stress and inflammation (248, 249),
thus amylin-impaired NO production may contribute to vascular oxidative stress
and inflammation. Extending from this, we can pursue to understand
hyperamylinemia effect on vascular smooth muscle cells, which directly
participate in vessel dilation/contraction. Because NO induces vascular smooth
muscle relaxation by decreasing intracellular calcium (250), we speculate that
defective NO production from ECs resulting from hyperamylinemia impairs
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vascular smooth muscle cell relaxation.
2. Astrocyte activation and reactive astrogliosis
Amylin deposition was found to localize with or nearby astrocytes in the
brain of AD patients (2, 129). Brains of patients with AD and T2D and HIP rats
show signs of astrocyte activation (2). Aggregated amylin causes a rapid
increase of calcium by disrupting ionic channels activity (251) and deranging
plasma and intracellular membrane (252) in the neuron. In glial cells, an
increased level of intracellular calcium can activate calcineurin, which
dephosphorylates the nuclear factor of activated T-cells (NFAT) (253).
Activated NFAT translocates into nuclear and facilitates the expression of
genes regulated astrocyte hypertrophy and inflammatory cytokines during
central nervous system injury (253). Interestingly, our previous works found that
hyperamylinemia is associated with intraneuronal amylin deposition and
increases inflammatory cytokine interleukin 1 (IL-1β) synthesis (99, 254), which
can lead to BBB dysfunction and increased permeability (2, 221, 255). Taken
together, we hypothesize that aggregated amylin activates astrocyte
hypertrophy and inflammatory signaling through calcium dysregulation. We
anticipate that human amylin-induced rise in astrocyte intracellular calcium
activates NFAT, marked by NFAT translocation to the nuclear and elevated IL1β expression. We postulate that the leaky endothelium resulted from the
accumulation of amylin, allows amylin entry to neighbor astrocytes, therefore
inducing calcium dyshomeostasis and triggering inflammation.
4.2.b. Studies on the mechanisms of amylin-induced changes in
metabolism and interaction with molecules involved in
neurodegeneration.
4.2.b.i Amylin alters the function of the neural cells in the
neurovascular unit
The neurovascular unit is a multicellular structure composed of the
endothelium and its BBB, extracellular matrix, pericytes, and neural cells
(neurons, astrocytes, neurons, and microglia) (161). This unit regulates BBB
permeability, cerebral blood flow, neuronal and synaptic functions through
changes in the blood flow (161). Reports from our lab (2, 99, 158) and others
(3, 4) indicate the toxic effects of aggregated amylin on endothelium layer (2),
neurons (99, 158), astrocytes (2), and pericytes (3, 4). Yet, the specific
pathological functions of aggregated amylin in each component of the
neurovascular unit and how those pathological functions interact with each
other have not been fully investigated. The following are proposed research
directions to decipher the role of aggregated human amylin in pathological
production of APOE4 from astrocytes and neurons, and in neurotransmitter
metabolism.
1. Amylin alters the function of the neural cells in the neurovascular
unit: APOE4 production from astrocytes and neurons
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Besides the liver, the brain is the second major source of APOE (190).
Astrocyte is the major cell type that secretes and lipidates APOE in the brain to
support lipid transport and membrane repair process (190, 256, 257). Microglia
and neurons also produce APOE in response to stressful conditions or injuries,
probably as part of cellular repair and remodeling (207). Emerging evidence
indicates that poorly lipidated APOE4 secreted by astrocytes during aging, a
preferable pathway compared to APOE3 secretion in healthy stage, disrupts
neuronal lipid homeostasis and neuronal membrane repair (258). Moreover,
neuronal-derived APOE4 promotes excitotoxicity (259). It is established that
human amylin causes neuronal insults through several mechanisms:
mitochondrial dysfunction, calcium dysregulation, and oxidative stress (99,
138, 145-149) (as discussed in Chapter 1). Our studies also show that human
amylin is associated with astrogliosis (2), increased accumulation of
parenchymal mixed plaques and vascular amyloid (Chapter 3). A recent study
shows that human amylin destabilizes the cell membrane of astrocyte and
causes mitochondrial stress and increases production of reactive oxygen
species (149). Therefore, we hypothesize that human amylin promotes APOE4
production from astrocytes and neurons in response to amylin-mediated
cellular injuries, leading to the degradation of the neurovascular unit. We
anticipate that the amylin-skewed APOE4 secretion disturbs neuronal
homeostasis and accelerates the neurodegenerative process. Moreover, we
speculate that elevated APOE4 levels in response to insults caused by amylin
can increase the formation of APOE4-Aβ and/or APOE4-amylin complex,
preventing proper clearance of amyloid out of the brain (Fig. 4.2).
2. Amylin alters the function of the neural cells in the neurovascular
unit: changes in neurotransmitter production
Patients with mild cognitive impairment and AD have alteration in tyrosine
and phenylalanine levels that affects cellular metabolism (260). We have
previously identified metabolic changes that are uniquely related to the amylindriven pathology, not hyperglycemia, in the brain chemistry of HIP rats (158).
HIP rat brains showed a deficiency in phenylalanine and tyrosine, which are
precursors for catecholamine neurotransmitters (dopamine, norepinephrine,
epinephrine). These changes possibly are due to altered glucose metabolism
in neurons (158), which are commonly seen in neurodegenerative diseases
(159). Both the reduction in the levels of neurotransmitter precursors and
alteration in pentose phosphate pathway correlate with the neurological
dysfunction in HIP rats ((2, 8) and Chapters 2 and 3). Since maintaining proper
neurotransmitter levels are essential for synaptic transmission and neuronal
health, we postulate that amylin-induced changes in tyrosine and
phenylalanine levels lead to defective synaptic transmission and synaptic
dysfunction, contributing to neurodegeneration (Fig. 4.2).
4.2.b.ii Amylin promotes Aβ production through intraneuronal
calcium dysfunction
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While the pathological function of aggregated amylin on endothelial cells
and pericytes have been investigated previously, much less is known about the
effects of aggregated amylin on neuronal and glial metabolism and function. In
vivo data in Chapter 3 suggest that amylin accumulation in the brain is
associated with increased Aβ accumulation. Works from other lab show that
amylin injection elevates Aβ production and Aβ-related pathology in AD mice
brains, through the increased expression of γ-secretase in lipid raft (142). Since
Aβ is produced by neurons and astrocytes, and its degradation is regulated by
other glial cells (261), amylin accumulation in the neurons (99) and possibly,
astrocytes/microglia, potentially influences Aβ production and degradation by
mechanisms involved amyloid-beta precursor protein (APP) metabolism, APP
internalization; and increased endosomal/lysosomal processing of toxic Aβ
species (262). Plausible mechanisms that mediate these processes comprise
of neuronal calcium regulation, as cellular calcium homeostasis is notoriously
affected by human amylin due to the disruption of the cellular membrane (as
discussed in Chapter 1).
Although compelling more studies, neuronal calcium dyshomeostasis has
been proposed to be a proximal cause of neurodegeneration in AD (263). It is
due to changes in calcium signaling at the initial stage of the disease and the
augmentation of Aβ formation, as well as Tau hyperphosphorylation during
calcium dyshomeostasis (263). Amylin forms pore on the plasma membrane
which allows extracellular Ca2+ influx (107-110, 146, 147), and can penetrate
and cause leakage of stored intracellular Ca2+ (146). There is limited
information about how amylin causes dysregulation in stored intracellular Ca2+
in neurons; however, extensive research efforts have demonstrated that amylin
perturbs cardiomyocyte endoplasmic/sarcoplasmic reticulum (the main
intracellular calcium storage) membrane permeation and induces Ca2+ leak
(124, 125). Hence, amylin possibly exerts the same effects on the endoplasmic
reticulum (ER) of other cell types, including neurons. In neurons, a large
fraction of Aβ42 is generated in the ER (264). ER is one of the compartments
where presenilin (PS) 1 and PS2 reside (265). Presenilins are components of
the γ-secretase complex that processes APP (265). It is undeniable that
presenilins have important roles in regulating ER calcium signaling, and all
clinical mutations of PS1 and PS2 have been shown to increase calcium load
and disrupt calcium signaling (263). Interestingly, modulation of intracellular
calcium both from the extracellular source and from the ER change Aβ
production (263). Therefore, amylin-induced changes in intracellular calcium by
causing a leak in the ER membrane may have potential effects in altering
presenilin function and Aβ production (Fig. 4.2).
4.2.b.iii Identify the mechanisms of amylin impairs clearance of
amyloid (amylin and Aβ) in the vasculature
Next, we propose that understanding how amylin inhibits amyloid clearance
through the brain blood vessels could be beneficial for therapeutic
development. One school of thought posits that in the late-onset AD, the
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accumulation of Aβ may not be caused by the increased production, but by the
inefficient clearance from the brain (266). Data from Chapter 3 (Fig. 3.1)
suggest the brain blood vessels of humans with familial AD contain amylin
accumulation, surrounding by Aβ deposits in the abluminal side of the blood
vessels or in the perivascular space. Similar pathology was also observed in
the brains of patients with sporadic AD (5). The luminal amylin deposits were
confirmed to be amyloid-rich in both familial and sporadic forms of AD (Chapter
3, (5)). These data indicate that the peripheral amylin accumulated in the
cerebral blood vessels may cause blockage of the Aβ drainage system. This
may be due to (a) amylin pathological functions in causing BBB injuries (results
from (2) and Chapter 3), which can deplete the receptors participated in
amyloid clearance process at the BBB; (b) amyloid formation by amylin
impedes Aβ translocation from the brain to the vascular lumen.
Another more complicated process of how parenchymal amylin-impaired Aβ
clearance may involve receptors at the BBB. The clearance of Aβ is a complex
process that engaged Aβ binding to transport proteins (e.g., APOE and APOJ)
and receptors on the endothelial cells of the BBB and ependymal cells of the
choroid plexus (e.g., low-density lipoprotein receptor (LDLR), low-density
lipoprotein receptor-related protein (LRP)) (266). APOE4 is known to affect Aβ
peptide clearance from the brain (207), specifically, APOE4 binding to Aβ
redirects Aβ clearance from LRP1 to VLDLR (very-low-density lipoprotein
receptor) at the BBB (267). The VLDLR internalizes Aβ-APOE4 complexes
more slowly than LRP1, making this a less efficient route (267). Interestingly,
studies from our lab (2) and other (208) demonstrate the ability of amylin to
bind to apolipoproteins including APOE4, which may decrease the efficiency of
its clearance from the brain and affect amyloid clearance. We hypothesize that
the accumulation of amylin in the brain (in both familial and sporadic AD
patients) can interfere with Aβ clearance at the BBB through two possible
mechanisms: 1) amylin competes with Aβ to bind directly to LRPs, and 2)
amylin competes with Aβ to bind to APOEs that participate in faster clearance
route through certain APOE receptors (Fig. 4.2). And this can slow the
clearance efficiency of amyloid from the brain, leading to the formation of
vascular amyloid and vascular damage.
4.3. Conclusions
Published studies have opened a new research paradigm on amylin as a
molecular link between the periphery, particularly pancreatic dysfunction, and
dementia. Our data show evidence for the role of pancreatic amylin in AD and
cerebral microvascular pathology and suggest that drugs reducing amylin
accumulation in brain capillaries or preventing amylin from interacting with Aβassociated pathology could provide benefit in patients with AD. Therefore,
targeting amylin dyshomeostasis may be an effective strategy to prevent or
slow the advancement of Alzheimer and cerebrovascular disease. This is of
clinical interest for several reasons. First, the administration of treatment in the
circulation is much less complicated and is easier to control than delivering
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treatment into the brain. Second, therapeutic interventions aiming to protect
specific biological components affected by amylin, and intervention during the
prediabetic stage may be more effective at preventing cellular injuries.
Future research should take into consideration that the pathophysiology of
amylin dyshomeostasis involves complex interactions of multiple deficiencies.
Therefore, the multi-facets of the subject require research models that can
represent the complexity of the disease to understand the underlying
mechanisms attributed to CVD or AD.
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FIGURES
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Figure 4.2. Proposed mechanisms for future laboratory studies. BBB: bloodbrain barrier; APOE: apolipoprotein; APP: amyloid precursor protein; LRP: lowdensity lipoprotein receptor-related protein; LDL-R: low-density lipoprotein
receptor; ER: endoplasmic reticulum; RBC: red blood cell.
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Figure 4.2.a.ii.1. Schematic view of proposed mechanism on aggregated
amylin inhibits insulin-mediated NO release from endothelium. IRS-1/2:
insulin receptor substrate 1/2; PI3K: phosphoinositide 3-kinase; Akt: protein
kinase B; eNOS: endothelial nitric oxide synthase; PKCβ: protein kinase C beta
type; CaMKII: Ca2+/calmodulin-dependent protein kinase II.
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